Side effects of cyproterone acetate

The side effects of cyproterone acetate (CPA), a steroidal antiandrogen and progestin, including its frequent and rare side effects, have been studied and characterized. It is generally well-tolerated and has a mild side-effect profile, regardless of dosage, when it used as a progestin or antiandrogen in combination with an estrogen such as ethinylestradiol or estradiol valerate in women. ^{[1] [2]} Side effects of CPA include hypogonadism and associated symptoms such as demasculinization, sexual dysfunction, infertility, and osteoporosis; breast changes such as breast tenderness, enlargement, and gynecomastia; emotional changes such as fatigue and depression; and other side effects such as vitamin B12 deficiency, weak glucocorticoid effects, and elevated liver enzymes. ^[3] Weight gain can occur with CPA when it is used at high doses. ^{[4] [5]} Some of the side effects of CPA can be improved or fully prevented if it is combined with an estrogen to prevent estrogen deficiency. ^{[6] [7]} Few quantitative data are available on many of the potential side effects of CPA. ^[8] Pooled tolerability data for CPA is not available in the literature. ^[9]

At very high doses in aged men with prostate cancer, CPA can cause cardiovascular side effects. Rarely, CPA can produce blood clots, liver damage, excessively high prolactin levels, prolactinomas, and meningiomas. Upon discontinuation from high doses, CPA can produce adrenal insufficiency as a withdrawal effect.

Overview

• v
• t
• e

Side effects of high-dose cyproterone acetate

Frequency	System Organ Class	Side effect
Very common (≥10%)	General disorders and administration site conditions	Headache Tiredness
	Psychiatric disorders	Decreased libido (men) Erectile dysfunction (men) Reduced ejaculate volume (men)
	Reproductive system and breast disorders	Reversible inhibition of spermatogenesis (men) Inhibition of ovulation and reversible infertility (women)
	Hepatobiliary disorders	Elevated liver enzymes
Common (≥1% and <10%)	Metabolism and nutrition disorders	Weight gain or loss (can be associated with fluid retention)
	Psychiatric disorders	Depressed mood Restlessness
	Reproductive system and breast disorders	Gynecomastia (men) Breast pain/tenderness Irregular menstruation
	General disorders and administration site conditions	Fatigue Hot flashes Sweating
	Respiratory, thoracic, and mediastinal disorders	Shortness of breath
	Gastrointestinal disorders	Nausea Gastrointestinal complaints
Uncommon (≥0.1% and <1%)	Psychiatric disorders	Decreased libido (women)
	Skin and subcutaneous tissue disorders	Rash
Rare (≥0.01% and <0.1%)	Immune system disorders	Hypersensitivity reactions (rash, itching, shortness of breath)
	Psychiatric disorders	Increased libido (women)
Very rare (<0.01%)	Neoplasms benign and malignant	Benign and malignant liver tumors
	Musculoskeletal and connective tissue disorders	Osteoporosis
	Cardiovascular disorders	Thromboembolic events Tachycardia
	Reproductive system and breast disorders	Galactorrhea
	General disorders and administration site conditions	Sleep disturbances
Unspecified	Unsorted	Anemia Meningioma Hyperprolactinemia Prolactinoma Intra-abdominal hemorrhage Breast tension Menstrual spotting Low Dysmenorrhea Vaginal discharge Skin discoloration Stretch marks Rare Liver toxicity (including jaundice, hepatitis, liver failure)
Notes: Side effects are for dosages of cyproterone acetate (Androcur) of 10 to 300 mg/day. Sources: See template.

• v
• t
• e

Side effects of cyproterone acetate in the SExual-HOrmonal Surveillance STudy (SEHOST)

Side effect	Males (136 mg/day) [a] (n = 1248) (%)	Females (18 mg/day) [a] (n = 1258) (%)	Total (77 mg/day) [a] (n = 2506) (%)
Elevated liver enzymes [b]	12.5	3.6	9.6
Gynecomastia, breast pain	4.9	1.0	2.9
Overweightness, weight gain	0.9	4.1	2.5
Headache, migraine	–	3.4	1.7
Depression, anxiety, nightmares, mood swings	1.0	1.8	1.4
Gastrointestinal dysfunction	0.2	2.3	1.2
Thyroid dysfunction	0.2	1.8	1.0
Skin changes (pigmentation, chloasma, others)	0.3	1.4	0.8
Edema	–	1.1	0.6
Adrenal insufficiency or hyperplasia	0.2	0.8	0.5
Tiredness, lethargy, apathy	0.6	0.6	0.6
Alopecia, hair growth	0.2	0.2	0.2
Increased asthma attack rates	–	0.3	0.2
Osteoporosis	0.2	0.08	0.2
More frequently prone to attacks	0.2	0.2	0.2
Diabetes mellitus	0.08	0.08	0.08
Total (excluding elevated liver enzymes)	9.0	19.1	14.0
Notes: Data from the SExual-HOrmonal Surveillance STudy (SEHOST), a long-term pharmacoepidemiologic active surveillance study. The sample included males and females age 3 to 75 years with precocious puberty, hyperandrogenism, sexual deviance, and/or transgenderism; prostate cancer was not included. Sources: See template.

• v
• t
• e

Side effects of estradiol undecylate versus cyproterone acetate in men

Side effect	Estradiol undecylate 100 mg/month i.m. (n = 96)		Cyproterone acetate 100 mg/day oral (n = 95)
	n	%	n	%
Gynecomastia*	74	77.1%	12	12.6%
Breast tenderness*	84	87.5%	6	6.3%
Sexual impotence	"Occurred in essentially all patients of both groups"
Leg edema*	17	17.7%	4	4.2%
Thrombosis	4	4.2%	5	5.3%
Cardiovascular mortality	2	2.1%	2	2.1%
Other mortality	1a	1.0%	0	0%
Notes: For 6 months in 191 men age 51 to 88 years with prostate cancer. Footnotes: * = Differences in incidences between groups were statistically significant. a = Due to unknown causes. Sources: See template.

Low hormone levels

Side effects in men resulting from the antiandrogenic and antigonadotropic properties of CPA include physical demasculinization, sexual dysfunction (including loss of libido and erectile dysfunction), absence of ejaculate, impaired spermatogenesis, testicular atrophy, and reversible infertility. ^{[10] [11]} CPA has been described as causing "severe" suppression of sex drive and erectile potency in men with prostate cancer, comparable to that seen with surgical castration. ^[12] Due to suppression of the production of estrogens, long-term use of high-dose CPA without concomitant estrogen therapy can result in the development of osteoporosis in both sexes. ^[13] CPA can also sometimes cause breast changes in men such as gynecomastia (breast growth), breast tenderness, and galactorrhea (milk outflow). ^{[10] [14] [15] [16] [9] [17]} The use of CPA in men has been associated with cellulite, which has been attributed to androgen deficiency as well. ^[18]

Breast changes

CPA can sometimes cause breast changes in men including gynecomastia (breast development) and breast tenderness. ^[10] Rates of gynecomastia of 4 to 30% have been reported. ^{[14] [15] [16] [9] [17]} Galactorrhea (milk outflow) can also occur in men, due to the strong progestogenic effects of CPA. ^[10]

Depression

CPA has occasionally been associated with depressive mood changes in both men and women. ^[19] Similar depressive changes have been observed with castration, and may be a consequence of androgen deprivation in men. ^[19] In large studies, the incidence of depression has been 1 to 10% in both women taking high-dose CPA in combination with an estrogen for androgen-dependent skin and hair conditions and men taking high-dose CPA alone or in conjunction with castration for prostate cancer. ^{[3] [20] [21]} In some small studies however, relatively high rates of depression of 20 to 30% have been reported with both low- and high-dose CPA in combination with an estrogen in women. ^{[22] [23] [24]} In one large randomized controlled trial that performed a direct head-to-head comparison of high-dose (100 mg/day) versus low-dose CPA (2 mg/day), both in combination with an estrogen, the overall rate of depression was 12.7% and the rates did not differ between the two groups. ^[5] Despite some association with depression, the incidence of depression in women taking CPA in combination with an estrogen has been described by some researchers as "remarkably low", which they have said may be related to the positive psychological effects of the improvement in androgenic symptoms. ^[3]

A randomized controlled trial comparing the cognitive and emotional effects of GnRH agonists and CPA in 82 men with prostate cancer found no significant differences in scores on the Depression Anxiety Stress Scale-21 (DASS-21) after 6 months of treatment. ^[25] However, a 12-month follow-up of 62 of the men found a significant increase in emotional distress as measured by the DASS-21 in the CPA and watchful waiting groups relative to the GnRH-agonist groups. ^{[26] [27]} Nonetheless, the mean levels of emotional distress remained within the normal range. ^[27]

A retrospective study reported that the rate of depression was greater with CPA (8.3%) than with GnRH analogues (2.2%) when both were used in combination with an estrogen in transgender women, although this study did not control for mood-related confounds. ^[28] Another retrospective study in transgender women, which used the Beck Depression Inventory‐II and other scales, found no significant differences in psychological well‐being or satisfaction with the combination of an estrogen and CPA or a GnRH agonist. ^[29] Hormone therapy in transgender women, including studies that used CPA, has been found to result in a significant decrease in depressive symptoms. ^{[30] [31]}

In a series of relatively small studies of the combination of low-dose CPA and ethinylestradiol as a birth control pill, depression was reported to have occurred in 1.3 to 4% of cycles. ^[32] This is similar to the rate of mood changes (<3.5%) observed with birth control pills containing other progestins. ^[32] A pharmacoepidemiological study using data from the United Kingdom General Practice Research Database found that the incidence of depression with birth control pills containing CPA was identical to that of birth control pills containing other progestins (IRR = 0.99). ^[33] In clinical studies of the combination of low-dose CPA and estradiol valerate for the treatment of menopausal symptoms, preexisting adverse mood symptoms have been found to be significantly improved. ^[34]

Because of the possible side effect of worsened depressive symptoms, it may be advisable to use CPA with caution in individuals with a history of depression, particularly if severe. ^[35]

Bone loss

Androgen deprivation therapy, with medications such as CPA or GnRH modulators or with orchiectomy, results in profound deficiency of both androgens and estrogens in men. ^{[36] [37]} These hormones, particularly estrogens, are known to be importantly involved in maintaining bone mineral density, both in men and women. ^{[36] [38]} As a result, androgen deprivation therapy causes a rapid decrease in bone mineral density in men and can result in osteopenia or osteoporosis with long-term therapy. ^{[36] [37]}

The bone loss that happens with androgen deprivation therapy typically occurs in the spine, hip, and forearm, but can also occur in other areas of the appendicular skeleton such as the femoral neck. ^[36] It can be seen within one year of treatment, and continues thereafter. ^[36] Lumbar spine bone density has been found to decrease at a rate of 3 to 7% per year with androgen deprivation therapy in men. ^[36] Androgen deprivation therapy also decreases muscle mass, and this may increase the risk of falls that can result in bone fractures as well as directly decrease bone mass. ^[36] The risk of bone fractures in men with prostate cancer given androgen deprivation therapy has been estimated to be increased by 45%. ^[36] The incidence of osteoporosis increases in men with prostate cancer from 36% to 80% after 10 years of androgen deprivation therapy, and following that, it can be expected that all treated men will develop osteopenia or osteoporosis. ^[39] The bone loss that occurs with androgen deprivation therapy in men is similar to that which occurs in postmenopausal women. ^[36]

Although androgen deprivation therapy is known to cause osteoporosis, it is thought that CPA may have a lower risk of osteoporosis than GnRH modulators or orchiectomy. ^[40] This is believed to be due to the progestogenic activity of CPA, which may help to inhibit bone resorption caused by sex-hormone deficiency. ^[40] However, the notion that progestogenic activity has beneficial effects on bone health is controversial. ^[41] Regardless of whether the notion is correct or not, case reports and case series of osteoporosis with CPA therapy in men have been published. ^{[40] [37]} Changes in biomarkers suggestive of bone loss have also been reported for high-dose CPA monotherapy. ^[42] In addition, the use of progestogen-only birth control in women, with progestins similar to CPA like medroxyprogesterone acetate, has been found to result in decreased bone mineral density in premenopausal women. ^{[43] [44]}

Calcium and vitamin D supplementation may help to reduce the risk of osteoporosis with androgen deprivation therapy in men. ^{[36] [39]} Bisphosphonates can be used to reduce bone loss and fractures due to androgen deprivation therapy. ^{[36] [39]} Estrogen replacement and selective estrogen receptor modulators may also be employed, although estrogens can produce gynecomastia in men and may increase the risk of male breast cancer. ^{[36] [39] [38]} Selective estrogen receptor modulators have been found to decrease the rate of bone loss due to androgen deprivation therapy in men by 50% after 2 years of therapy. ^[39] However, selective estrogen receptor modulators are described as substantially less effective for this indication than estrogens, which are the most effective medications for this purpose available. ^[45]

High progestogenic exposure

High prolactin levels

CPA increases prolactin levels and can produce hyperprolactinemia (high prolactin levels) due to its progestogenic activity and consequent stimulation of pituitary lactotrophs. ^{[46] [47] [48] [49] [50] [51] [52] [53] [54] [55]} Increases in prolactin levels can occur at low, medium, and high doses of CPA, with or without an estrogen. ^[3] Elevation of prolactin levels may be greater and hyperprolactinemia more likely to occur when CPA is combined with an estrogen, as combinations of estrogens and progestogens show synergistic increases in prolactin levels in non-human primates. ^{[56] [57] [58]} Although hyperprolactinemia can develop with CPA, prolactin levels only rarely exceed the normal physiological range, and increased prolactin levels with CPA are said to be seldom of clinical significance. ^[3]

At a dosage of 10 mg/day in men, CPA has been found to increase prolactin levels by 75%. ^{[59] [60] [61]} In another study, a combination of 2 or 20 mg/day CPA with testosterone undecanoate resulted in modest increases in prolactin levels (+96%) in men similarly. ^[62] The increase in prolactin levels in men with 100 mg/day oral CPA (+118%) has been found to be less than that with 100 mg/month intramuscular estradiol undecylate (+192%). ^[47] The combination of high-dose (100 μg/day) ethinylestradiol and high-dose (100 mg/day) oral CPA in transgender women has been reported to increase the risk of hyperprolactinemia by 425-fold (20% incidence) relative to cisgender men. ^[63] However, other studies using the same regimen have found lower incidences of hyperprolactinemia (e.g., 4–7% per year). ^{[64] [65]} In one study, prolactin levels were 18 ng/mL at the start of treatment, 23 ng/mL after 3 months of 100 mg/day CPA, and 19 to 28 ng/mL after 6 to 15 months of 100 μg/day ethinylestradiol and 100 mg/day oral CPA in transgender women. ^[65]

The major symptom of hyperprolactinemia as a condition is hypogonadism, which is caused by the antigonadotropic effects of prolactin. ^[55] Symptoms consequent to hypogonadism include amenorrhea, menopausal symptoms like hot flashes and vaginal dryness, sexual dysfunction, infertility, reduced muscle mass, and decreased bone mineral density. ^{[55] [66] [67]} However, due to its progestogenic actions and the potent antigonadotropic effects produced by this activity, CPA can produce such symptoms as side effects regardless of the presence or absence of hyperprolactinemia. ^{[11] [36] [13]}

Prolactin additionally appears to have a direct inhibitory effect on sexual desire in men that is independent of hypogonadism. ^{[68] [69] [70]} In men with hyperprolactinemia and hypogonadism, sexual desire is not restored by testosterone replacement therapy, but is restored by prolactin-suppressing medications. ^{[68] [69]} Conversely, erectile dysfunction in men with hyperprolactinemia is considered to be due to hypogonadism rather than due to direct actions of prolactin itself. ^[68] On the other hand, it is thought that prolactin may be responsible for the normal sexual refractory period in men, and may directly inhibit the capacity for orgasm. ^[70]

In addition to symptoms of hypogonadism and sexual dysfunction, hyperprolactinemia can cause breast changes such as breast pain, breast enlargement, gynecomastia, and galactorrhea. ^{[55] [71] [72]} Galactorrhea secondary to hyperprolactinemia is very common in premenopausal women (80%) but more uncommon in individuals with low estrogen levels such as postmenopausal women and men. ^[71] Gynecomastia likewise occurs at a relatively low rate in men with hyperprolactinemia (23%). ^[71] Studies in transgender women have found low but significant incidences of galactorrhea with the combination of estrogen and CPA. ^{[65] [73] [74]}

Prolactin increases levels of adrenal androgens like dehydroepiandrosterone and dehydroepiandrosterone sulfate by increasing their production and secretion from the adrenal glands. ^{[75] [76] [77] [78]} For this reason, hyperprolactinemia can cause symptoms of hyperandrogenism such as acne and hirsutism in women. ^{[55] [79]} However, such symptoms are not described with CPA, which instead treats these conditions; this can be attributed to the antiandrogenic and glucocorticoid activity of CPA. ^[3] Through such activities, CPA directly blocks the actions of androgens and can suppress dehydroepiandrosterone sulfate secretion from the adrenal glands. ^{[3] [80] [81] [7]}

Brain tumors

The combination of an estrogen and CPA has been associated, albeit rarely, with the incidence and/or aggravation of a few different types of usually benign (non-cancerous) brain tumors, most notably prolactinomas and meningiomas. ^{[82] [83]} Prolactinomas are benign tumors of the pituitary gland that secrete prolactin, and are one of several types of secreting pituitary adenomas. ^{[65] [63]} They can produce hyperprolactinemia (abnormally high prolactin levels) as a symptom, which often leads to their diagnosis. ^{[65] [63]} Meningiomas are usually-benign tumors of the meninges, the membranes that envelop the brain and spinal cord. ^{[84] [85]} Due to its association with meningiomas, CPA is considered to be contraindicated in people with meningioma or a history of meningioma. ^{[86] [35]} Benign brain tumors associated with an estrogen and/or CPA can cause visual disturbances or in severe cases complete blindness due to compression of the optic nerve and/or chiasm. ^[82]

Meningiomas are 2 to 3 times as prevalent in women than in men, and acceleration of meningioma growth has been observed during pregnancy and in the luteal phase of the menstrual cycle, indicating a possible hormonal link. ^[87] There is expression of the PR in the anterior pituitary and high expression of the PR in the meninges, suggesting that activation of the PR by CPA is involved in the pathogenesis of the benign brain tumors associated with it. ^[88] Estrogen receptors are also expressed in the anterior pituitary, ^[89] and are known to increase the expression of the PR in this area. ^[90] In accordance, estrogens and progestogens, including CPA, are known to increase prolactin levels, particularly at high concentrations (e.g., pregnancy). ^{[53] [91]} While most cases of benign brain tumors associated with CPA have been in combination with an estrogen and have occurred in transgender women, there have been cases associated with high-dose CPA alone in both cisgender women and men as well. ^{[56] [92]} Benign brain tumors such as meningiomas have also been associated with high doses of other progestogens, such as chlormadinone acetate, megestrol acetate, medroxyprogesterone acetate, and nomegestrol acetate, as well as with pregnancy. ^{[87] [93] [94] [95] [96]}

A number of case reports of prolactinomas (as well as a non-secreting pituitary adenoma), ^{[97] [98] [99] [100] [101]} meningiomas, ^{[102] [103] [104] [105] [93] [92] [82]} and vestibular schwannomas ^[83] associated with estrogen and CPA therapy in transgender women have been published. ^{[106] [107] [108] [83] [87] [109]} A large retrospective chart study of 2,555 transgender women treated most frequently with an estrogen and CPA and followed for 23,935 person-years reported occurrences of 8 meningiomas (0.31% or 1 in 320 incidence; SIR = 4.1 relative to cisgender females, SIR = 11.9 relative to cisgender males), 9 prolactinomas (0.35% or 1 in 284 incidence; SIR = 4.3 relative to cisgender females, SIR = 26.5 relative to cisgender males), one non-secreting pituitary adenoma, and two vestibular schwannomas. ^[83] A retrospective study of 303 transgender women treated with high-dose estrogen and CPA and followed for a median 4.4 years (range 6 months to 6 months to 14 years) reported occurrences of 46 cases of hyperprolactinemia (serum prolactin >1,000 mU/L) (15% incidence; 400-fold increased risk relative to cisgender males). ^{[63] [64] [108] [65] [110]} Of 23 persistent cases, 15 of which returned for follow up, 5 of the cases showed an enlarged pituitary gland on CT scanning with contrast enhancement. ^[63] Dosages of CPA in combination with an estrogen that have been associated with benign brain tumors have been 10 mg/day and above. ^{[83] [64] [109] [92]} In contrast to the combination of an estrogen and CPA, estrogen alone has been associated only with single case reports of prolactinomas in transgender women. ^{[110] [111] [83]}

A nationwide population study in Denmark found no significant association of CPA or other antiandrogens with meningioma in men. ^[112] However, studies in Spain and the United Kingdom have found positive associations of CPA therapy with meningioma. ^[112]

A hemangioblastoma mimicking a meningioma has been reported in a man treated with CPA. ^[113]

• v
• t
• e

Published case reports of cyproterone acetate-associated prolactinoma

#	Age	Sex	Medications	Treatment duration	Ref	Link
1	26 years	MtF	CPA 100 mg/day, EE 100 μg/day, EU 100 mg/2x week	~10 months	Gooren et al. (1988)	[114]
2	32 years	MtF	CPA 150 mg/day, EE 1.5 mg/day	4 years	Serri et al. (1996)	[115]
3	52 years	MtF	CPA 100 mg/day, EE 100 μg/day	15 years	Bunck et al. (2009)	[116]
4	33 years	MtF	CPA 200 mg/day, CEEs 2.5 mg/day	6 months	García-Malpartida et al. (2010)	[117]
5	41 years	MtF	CPA 2 mg/day, EE 35 μg/day, E2-EN 10 mg/2 weeks i.m.	18 years	Cunha et al. (2015)	[118]
6	32 years	MtF	CPA 100 mg/day, E2 injections 100 mg/2 weeks i.m.	53 months	Nota et al. (2018)	[119]
7	39 years	MtF	CPA 100 mg/day, CEEs 2.5 mg/day	172 months	Nota et al. (2018)	[119]
8	27 years	MtF	CPA, E2 injections i.m. (no dosage information)	156 months	Nota et al. (2018)	[119]
9	46 years	MtF	CPA 100 mg/day, EE 100 μg/day	66 months	Nota et al. (2018)	[119]
10	24 years	MtF	CPA 100 mg/day (no estrogen mentioned)	9 months	Nota et al. (2018)	[119]
11	47 years	MtF	CPA 100 mg/day, EE 100 μg/day	91 months	Nota et al. (2018)	[119]
12	28 years	MtF	CPA 50 mg/day, EV 2 mg/day oral	134 months	Nota et al. (2018)	[119]
13a	34 years	MtF	CPA 50 mg/day, EV 1 mg/day oral	35 months	Nota et al. (2018)	[119]
Abbreviations: CPA = Cyproterone acetate. E2 = Estradiol. EV = Estradiol valerate. E2-EN = Estradiol enanthate. EU = Estradiol undecylate. CEEs = Conjugated estrogens. EE = Ethinylestradiol. MtF = Male-to-female (transgender woman). i.m. = Intramuscular injection. Footnotes:a = Non-secretive pituitary adenoma. Notes: Asscheman et al. (1988) also described 5 MtF cases of pituitary enlargement and possible prolactinoma. [120] van Kesteren et al. (1997) described possible MtF cases of pituitary enlargement as well. [121] Five estrogen-only MtF cases (without CPA) have also been reported. [122] [116] [118] [119] Futterweit (1998) described an MtF case without information about medications. [123] Sources: [124]

• v
• t
• e

Published case reports of cyproterone acetate-associated meningioma

#	Age	Sex	Medications	Treatment duration	Ref	Link
1	28 years	MtF	CPA 100 mg/day, EE 100 μg/day	5 years	Gazzeri et al. (2007)	[125]
2	48 years	MtF	CPA 100 mg/day, EE ("feminizing regimen")	10 years	Cebula et al. (2010)	[126]
3	46 years	Female	CPA 50 mg/day, E2 ("substitutive")	10 years	Gonçalves et al. (2010)	[127]
4	83 years	Male	CPA ≥50 mg/day	2 years	Gil et al. (2011)	[128]
5	71 years	Male	CPA ≥50 mg/day	3 years	Gil et al. (2011)	[128]
6	66 years	Female	CPA ≥50 mg/day	3 years	Gil et al. (2011)	[128]
7	43 years	Female	CPA ≥50 mg/day	2 years	Gil et al. (2011)	[128]
8	35 years	MtF	CPA 100 mg/day, E2 100 μg/day patch	4 years	Bergoglio et al. (2012)	[129]
9	60 years	MtF	CPA 50 mg/day, E2 8 mg/day oral	10 years	Knight et al. (2013)	[130]
10	56 years	MtF	CPA, EV 2 mg/day oral	8 years	Razavi (2014)	[131]
11	51 years	Female	CPA 15 mg/day	30 years	Bernat et al. (2015)	[132]
12	47 years	Female	CPA 25 mg/day	15 years	Bernat et al. (2015)	[132]
13	43 years	Female	CPA 50 mg/day	12 years	Bernat et al. (2015)	[132]
14	39 years	Female	CPA 50 mg/day	10 years	Bernat et al. (2015)	[132]
15	61 years	Female	CPA 25 mg/day	24 years	Bernat et al. (2015)	[132]
16	38 years	Female	CPA 25 mg/day	10 years	Bernat et al. (2015)	[132]
17	45 years	Female	CPA 50 mg/day	20 years	Bernat et al. (2015)	[132]
18	53 years	Female	CPA 50 mg/day	20 years	Bernat et al. (2015)	[132]
19	56 years	Female	CPA 50 mg/day	8 years	Bernat et al. (2015)	[132]
20	55 years	Female	CPA 50 mg/day	30 years	Bernat et al. (2015)	[132]
21	49 years	Female	CPA 50 mg/day	20 years	Bernat et al. (2015)	[132]
22	49 years	Female	CPA 50 mg/day	25 years	Bernat et al. (2015)	[132]
23	58 years	Female	CPA 50 mg/day	18 years	Botella et al. (2015)	[133]
24	37 years	Female	CPA 50 mg/day	11 years	Botella et al. (2015)	[133]
25	42 years	Male	CPA 100 mg/day	23 years	Sys & Kestelyn (2015)	[134]
26	45 / 46 years	MtF	CPA 10 or 100 mg/day, E2 20 mg/4 months implant	5 years	ter Wengel et al. (2015)	[135] [136]
27	51 years	MtF	CPA 100 mg/day, EE 100 μg/day	25 years	ter Wengel et al. (2015)	[135] [136]
28	65 years	MtF	CPA 10 mg/day, CEEs 1.25 mg/day	19 years	ter Wengel et al. (2015)	[135] [136]
29	26 years	Female	CPA 50 mg/day	10 years	Kalamarides & Peyre (2017)	[137]
30	43 years	Female	CPA 25 mg/day	25 years	Kalamarides & Peyre (2017)	[137]
31	83 years	Male	CPA 200 mg/day	7 months	Keilani & Abada (2017)	[138]
32	65 years	Female	CPA 50 mg/day	15 years	Bernat et al. (2018)	[139]
33	77 years	MtF	CPA 50 mg/day, E2 50 μg/day patch	24 years	Boer et al. (2018)	[140]
34	41 years	MtF	CPA 50 mg/day, E2 gel 1–3 mg/day	9 years	Mancini et al. (2018)	[141]
35	60 years	MtF	CPA, CEEs	36 years	Nizar & Seal (2018)	[142]
36	51 years	MtF	CPA 20 mg/week, E2 100 μg/day patch	11 years	Nota et al. (2018)	[136]
37	66 years	MtF	CPA 10 mg/day	40 years	Nota et al. (2018)	[136]
38	58 years	MtF	CPA 50 mg/day, E2 100 μg/day patch	6 years	Nota et al. (2018)	[136]
39	49 years	MtF	CPA, EV 2 mg/day	16 years	Nota et al. (2018)	[136]
40	51 years	MtF	CPA 100 mg/day, EE 100 μg/day patch	26 years	Nota et al. (2018)	[136]
41	50 years	MtF	CPA 50 mg/day, E2 0.6 mg/g cream 2x/day	~10 years	Raj et al. (2018)	[143]
42	48 years	MtF	CPA 50 mg/day, E2 1 mg/g cream 3x/day	21 years	Raj et al. (2018)	[143]
43	43 years	Female	CPA 25–50 mg/day, EV 2 mg/day, finasteride 5 mg/day, others	23 years	Chasseur et al. (2019)	[144]
44	67 years	MtF	CPA, estrogen	>14 years	Alalade et al. (2019)	[145]
45	46 years	Female	CPA 5 mg/day, subsequently NOMAC 5 mg/day	15 years	Champagne et al. (2019)	[146]
46	58 years	Female	CPA 25–100 mg/day for 10 days/cycle	34 years	Owens et al. (2019)	[147]
47	?	Male	CPA 300 mg/2 weeks i.m., leuprorelin 11.25 mg/3 months i.m.	?	Colstrup et al. (2020)	[148]
Abbreviations: CPA = Cyproterone acetate. E2 = Estradiol. EV = Estradiol valerate. CEEs = Conjugated estrogens. EE = Ethinylestradiol. MtF = Male-to-female (transgender woman). Notes: For the Bernat et al. (2015) cases, only one was reported to be taking an estrogen (specifically estradiol). [132] Froelich et al. (2008) reported an additional 8 female cases (age 33–62 years, mean 46 years; 50 mg/day CPA; 10–20 years exposure) with multiple meningiomas. [149] Cea-Soriano et al. (2012) also reported 8 cases (4 male (≥50 mg/day, OR Tooltip odds ratio = 3.28), 4 female (2 mg/day, OR = 1.03)) with no individual specifics. [133] [150] Peyre et al. reported 38 operated cases. [151] Portet et al. (2019) reported 30 operated cases. [152] Cases in association with other progestins have been reported as well. [132] Deipolyi, Han, & Parsa (2010) reported a case in an MtF in association with E2 100 μg/day only. [153] Sources: [135] [141] [154]

Blood clots

The combination of low-dose (2 mg) CPA in combination with ethinylestradiol (35 μg), as in combined birth control pills, presents an increased risk of venous thromboembolism (VTE). ^{[155] [156]} Women who take contraceptive pills containing CPA have a 6- to 7-fold increased risk of developing VTE compared to women not taking a contraceptive pill, and twice the risk of women who take a contraceptive pill containing the androgenic progestin levonorgestrel. ^[157] The absolute risk of VTE with ethinylestradiol and low-dose CPA-containing birth control pills is about 1 to 10 per 10,000 woman-years. ^[156] At least four publicized cases of fatal VTE have been attributed to birth control pills containing ethinylestradiol and low-dose CPA. ^[158] The progestogenic, antiandrogenic, and glucocorticoid activities of CPA are all thought to be involved in the increased risk of VTE with CPA in combination with estrogens. ^{[159] [160]}

The combination of oral 100 μg/day ethinylestradiol and 100 mg/day CPA was reported to produce a 45-fold increase in the risk of VTE in 303 transgender women, with an absolute incidence of 6.3% (19 cases). ^[161] The risk was highly age-dependent, with a rate of VTE of 2.1% in those less than 40 years of age and of 12% in those over 40 years of age. ^[161] In a subsequent study of 816 transgender women in whom the same regimen was used but transdermal estradiol had become the standard therapy for those over the age of 40, the risk of VTE was still increased overall by 20-fold (45 cases, 5.5% incidence). ^[161] However, there was only a single case of VTE in the group of 138 transgender women treated with transdermal estradiol (0.7% incidence). ^[161] In accordance, the combination of transdermal estradiol and 50 mg/day cyproterone acetate appears to be relatively safe in terms of VTE risk. ^[161] The VTE risk was initially attributed exclusively to ethinylestradiol, and the use of ethinylestradiol has largely been abandoned in transgender women in favor of other estrogens such as estradiol because of it. ^[161] However, CPA is now known to significantly increase the risk of VTE as well, and it may have contributed also. ^[161] CPA should be discontinued in transgender women after sex reassignment surgery or orchiectomy to reduce the risk of VTE. ^[161] It should also be discontinued at least 2 weeks before undergoing surgery to reduce the risk of VTE. ^[161]

A large pharmacoepidemiological study in the United Kingdom using the General Practice Research Database assessed the risk of VTE with various forms of androgen deprivation therapy for prostate cancer. ^{[162] [163] [164]} The study had a sample of 11,199 men, of whom 229 (2.0%) experienced VTE and in whom 14% this was fatal. ^{[162] [164]} The incidence rates for VTE were 3.46 for CPA monotherapy relative to nonsteroidal antiandrogen monotherapy with flutamide or bicalutamide; 3.35 for CPA monotherapy relative to GnRH agonist/orchiectomy monotherapy; 1.25 for CPA monotherapy relative to estrogen monotherapy with diethylstilbestrol or estramustine phosphate; and 0.60 for CPA monotherapy relative to combined androgen blockade with a GnRH agonist/orchiectomy and CPA. ^{[163] [8]} The adjusted odds ratios for VTE were 1.00 for no treatment; 1.29 for nonsteroidal antiandrogen therapy; 3.35 for combined androgen blockade with CPA and a GnRH agonist/orchiectomy; 5.23 for CPA monotherapy; and 5.67 for estrogen monotherapy. ^{[162] [164] [165]} The adjusted odds ratios for VTE of different dosages of CPA with or without a GnRH agonist relative to GnRH agonist monotherapy were 3.49 for 25 or 50 mg/day, 4.93 for 100 or 150 mg/day, and 4.54 for greater than or equal to 200 mg/day. ^[164] In addition to CPA and other medications used to treat prostate cancer, metastatic prostate cancer is itself a risk factor for VTE. ^[161]

In large randomized controlled trials of CPA versus other medications for the treatment of prostate cancer, the following incidences of VTE have been observed: 5.3% for 100 mg/day oral CPA (n = 95) vs. 4.2% for 100 mg/month intramuscular estradiol undecylate (n = 96); ^{[166] [167]} 2.4% for 250 mg/day oral CPA (n = 82) vs. 6.1% for 200 mg/day oral medroxyprogesterone acetate (n = 73) vs. 8.2% for 3 mg/day oral diethylstilbestrol (n = 114) (EORTC Trial 30761); ^{[168] [169]} and 4.5% for 300 mg/day oral CPA (n = 130) vs. 0% for 750 mg/day flutamide (n = 134). ^{[168] [170]} However, the final analysis of the last study (EORTC Trial 30892) indicated that VTE ultimately ended up occurring in 3 patients (2.0%) in the flutamide group (n = 151) and 7 patients (4.6%) in the CPA group (n = 152). ^[16] For further comparison, in another similar and closely related trial (EORTC Trial 30762), the incidence of VTE was 6.3% with 3 mg/day oral diethylstilbestrol (n=112) and 7.9% with 280–560 mg/day oral estramustine phosphate (n = 114). ^[169]

Premenopausal women using depot injectable medroxyprogesterone acetate, a progestin related to CPA, as a form of progestogen-only birth control, have been observed to have a 2.2- to 3.6-fold increased risk of VTE. ^{[171] [172]} However, this could have reflected preferential prescription of DMPA to women considered to be at an increased risk of VTE. ^[172] DMPA has little or no effect on coagulation and fibrinolytic factors. ^{[173] [174]} In addition, progestogens by themselves at physiological doses normally do not increase the risk of thrombosis. ^{[172] [175]}

• v
• t
• e

Risk of venous thromboembolism (VTE) with hormone therapy and birth control (QResearch/CPRD)

Type	Route	Medications	Odds ratio (95% CI Tooltip confidence interval)
Menopausal hormone therapy	Oral	Estradiol alone     ≤1 mg/day     >1 mg/day	1.27 (1.16–1.39)* 1.22 (1.09–1.37)* 1.35 (1.18–1.55)*
		Conjugated estrogens alone     ≤0.625 mg/day     >0.625 mg/day	1.49 (1.39–1.60)* 1.40 (1.28–1.53)* 1.71 (1.51–1.93)*
		Estradiol/medroxyprogesterone acetate	1.44 (1.09–1.89)*
		Estradiol/dydrogesterone     ≤1 mg/day E2     >1 mg/day E2	1.18 (0.98–1.42) 1.12 (0.90–1.40) 1.34 (0.94–1.90)
		Estradiol/norethisterone     ≤1 mg/day E2     >1 mg/day E2	1.68 (1.57–1.80)* 1.38 (1.23–1.56)* 1.84 (1.69–2.00)*
		Estradiol/norgestrel or estradiol/drospirenone	1.42 (1.00–2.03)
		Conjugated estrogens/medroxyprogesterone acetate	2.10 (1.92–2.31)*
		Conjugated estrogens/norgestrel     ≤0.625 mg/day CEEs     >0.625 mg/day CEEs	1.73 (1.57–1.91)* 1.53 (1.36–1.72)* 2.38 (1.99–2.85)*
		Tibolone alone	1.02 (0.90–1.15)
		Raloxifene alone	1.49 (1.24–1.79)*
	Transdermal	Estradiol alone    ≤50 μg/day    >50 μg/day	0.96 (0.88–1.04) 0.94 (0.85–1.03) 1.05 (0.88–1.24)
		Estradiol/progestogen	0.88 (0.73–1.01)
	Vaginal	Estradiol alone	0.84 (0.73–0.97)
		Conjugated estrogens alone	1.04 (0.76–1.43)
Combined birth control	Oral	Ethinylestradiol/norethisterone	2.56 (2.15–3.06)*
		Ethinylestradiol/levonorgestrel	2.38 (2.18–2.59)*
		Ethinylestradiol/norgestimate	2.53 (2.17–2.96)*
		Ethinylestradiol/desogestrel	4.28 (3.66–5.01)*
		Ethinylestradiol/gestodene	3.64 (3.00–4.43)*
		Ethinylestradiol/drospirenone	4.12 (3.43–4.96)*
		Ethinylestradiol/cyproterone acetate	4.27 (3.57–5.11)*
Notes: (1) Nested case–control studies (2015, 2019) based on data from the QResearch and Clinical Practice Research Datalink (CPRD) databases. (2) Bioidentical progesterone was not included, but is known to be associated with no additional risk relative to estrogen alone. Footnotes: * = Statistically significant (p < 0.01). Sources: See template.

Cardiovascular health

High-dose CPA for prostate cancer in men is associated with incidence of relatively mild cardiovascular side effects. ^{[176] [177] [178] [179] [180]} These include coagulation changes ^[181] and blood clots (5%), ^{[176] [182]} fluid retention (4%), ^[182] ischemic cardiomyopathy (4–40%), ^{[9] [183]} and undesirable effects on serum lipid profiles. ^{[176] [177] [178] [179] [180]} Severe cardiovascular complications occur in up to 10% at such doses and are sometimes fatal. ^{[180] [184]} A large randomized controlled trial that compared CPA and flutamide in men with prostate cancer found that the rates of cardiovascular problems were not significantly different between the two therapies. ^[16] The cardiovascular toxicity of 250 mg/day CPA is significantly lower than that of 3 mg/day diethylstilbestrol. ^{[168] [185]}

Breast cancer

The Women's Health Initiative randomized controlled trials demonstrated a significantly increased risk of breast cancer with 0.625 mg/day conjugated estrogens and 2.5 mg/day medroxyprogesterone acetate (a progestin closely related to CPA) for menopausal hormone therapy relative to 0.625 mg/day conjugated estrogens alone and placebo in peri- and postmenopausal women. ^{[186] [187]} Similarly, estrogen plus low-dose CPA for menopausal hormone therapy has been associated with a significantly higher risk of breast cancer relative to estrogen alone and no use. ^[188] In addition, a nationwide observational study found that estrogen plus high-dose CPA was associated with a 46-fold increased risk of breast cancer in transgender women relative to the expected incidence for cisgender men. ^{[189] [190] [191] [192]}

• v
• t
• e

Risk of breast cancer with menopausal hormone therapy in large observational studies (Mirkin, 2018)

Study	Therapy	Hazard ratio (95% CI Tooltip confidence interval)
E3N-EPIC: Fournier et al. (2005)	Estrogen alone	1.1 (0.8–1.6)
	Estrogen plus progesterone     Transdermal estrogen     Oral estrogen	0.9 (0.7–1.2) 0.9 (0.7–1.2) No events
	Estrogen plus progestin     Transdermal estrogen     Oral estrogen	1.4 (1.2–1.7) 1.4 (1.2–1.7) 1.5 (1.1–1.9)
E3N-EPIC: Fournier et al. (2008)	Oral estrogen alone	1.32 (0.76–2.29)
	Oral estrogen plus progestogen      Progesterone      Dydrogesterone      Medrogestone      Chlormadinone acetate      Cyproterone acetate      Promegestone      Nomegestrol acetate      Norethisterone acetate      Medroxyprogesterone acetate	Not analyzeda 0.77 (0.36–1.62) 2.74 (1.42–5.29) 2.02 (1.00–4.06) 2.57 (1.81–3.65) 1.62 (0.94–2.82) 1.10 (0.55–2.21) 2.11 (1.56–2.86) 1.48 (1.02–2.16)
	Transdermal estrogen alone	1.28 (0.98–1.69)
	Transdermal estrogen plus progestogen      Progesterone      Dydrogesterone      Medrogestone      Chlormadinone acetate      Cyproterone acetate      Promegestone      Nomegestrol acetate      Norethisterone acetate      Medroxyprogesterone acetate	1.08 (0.89–1.31) 1.18 (0.95–1.48) 2.03 (1.39–2.97) 1.48 (1.05–2.09) Not analyzeda 1.52 (1.19–1.96) 1.60 (1.28–2.01) Not analyzeda Not analyzeda
E3N-EPIC: Fournier et al. (2014)	Estrogen alone	1.17 (0.99–1.38)
	Estrogen plus progesterone or dydrogesterone	1.22 (1.11–1.35)
	Estrogen plus progestin	1.87 (1.71–2.04)
CECILE: Cordina-Duverger et al. (2013)	Estrogen alone	1.19 (0.69–2.04)
	Estrogen plus progestogen      Progesterone     Progestins         Progesterone derivatives         Testosterone derivatives	1.33 (0.92–1.92) 0.80 (0.44–1.43) 1.72 (1.11–2.65) 1.57 (0.99–2.49) 3.35 (1.07–10.4)
Footnotes:a = Not analyzed, fewer than 5 cases. Sources: See template.

Other long-term effects

In terms of ovulation inhibition, the effective dosage of CPA is 1.0 mg/day while that of medroxyprogesterone acetate is 10 mg/day. ^{[159] [193]} Based on ovulation inhibition, a dosage of 50 mg/day cyproterone acetate has on the order of 200 times the progestogenic potency of 2.5 mg/day medroxyprogesterone acetate. ^{[159] [193]} In addition to its progestogenic activity, CPA produces androgen and estrogen deficiency when used as a monotherapy, ^[194] and this influences health as well. ^{[195] [196] [38]}

The health effects of high-dose CPA with long-term therapy have not been well-studied. A meta-analysis of high-dose CPA for the treatment of prostate cancer in men found that CPA was associated with a slight excess of non-prostate cancer deaths. ^[197] In addition, the combination of CPA with surgical or medical castration for prostate cancer has been found to significantly decrease overall survival relative to castration alone. ^[198]

• v
• t
• e

Results of the Women's Health Initiative (WHI) menopausal hormone therapy randomized controlled trials

Clinical outcome	Hypothesized effect on risk	Estrogen and progestogen (CEs Tooltip conjugated estrogens 0.625 mg/day p.o. + MPA Tooltip medroxyprogesterone acetate 2.5 mg/day p.o.) (n = 16,608, with uterus, 5.2–5.6 years follow up)			Estrogen alone (CEs Tooltip Conjugated estrogens 0.625 mg/day p.o.) (n = 10,739, no uterus, 6.8–7.1 years follow up)
		HR Tooltip Hazard ratio	95% CI Tooltip Confidence interval	AR Tooltip Attributable risk	HR Tooltip Hazard ratio	95% CI Tooltip Confidence interval	AR Tooltip Attributable risk
Coronary heart disease	Decreased	1.24	1.00–1.54	+6 / 10,000 PYs	0.95	0.79–1.15	−3 / 10,000 PYs
Stroke	Decreased	1.31	1.02–1.68	+8 / 10,000 PYs	1.37	1.09–1.73	+12 / 10,000 PYs
Pulmonary embolism	Increased	2.13	1.45–3.11	+10 / 10,000 PYs	1.37	0.90–2.07	+4 / 10,000 PYs
Venous thromboembolism	Increased	2.06	1.57–2.70	+18 / 10,000 PYs	1.32	0.99–1.75	+8 / 10,000 PYs
Breast cancer	Increased	1.24	1.02–1.50	+8 / 10,000 PYs	0.80	0.62–1.04	−6 / 10,000 PYs
Colorectal cancer	Decreased	0.56	0.38–0.81	−7 / 10,000 PYs	1.08	0.75–1.55	+1 / 10,000 PYs
Endometrial cancer	–	0.81	0.48–1.36	−1 / 10,000 PYs	–	–	–
Hip fractures	Decreased	0.67	0.47–0.96	−5 / 10,000 PYs	0.65	0.45–0.94	−7 / 10,000 PYs
Total fractures	Decreased	0.76	0.69–0.83	−47 / 10,000 PYs	0.71	0.64–0.80	−53 / 10,000 PYs
Total mortality	Decreased	0.98	0.82–1.18	−1 / 10,000 PYs	1.04	0.91–1.12	+3 / 10,000 PYs
Global index	–	1.15	1.03–1.28	+19 / 10,000 PYs	1.01	1.09–1.12	+2 / 10,000 PYs
Diabetes	–	0.79	0.67–0.93		0.88	0.77–1.01
Gallbladder disease	Increased	1.59	1.28–1.97		1.67	1.35–2.06
Stress incontinence	–	1.87	1.61–2.18		2.15	1.77–2.82
Urge incontinence	–	1.15	0.99–1.34		1.32	1.10–1.58
Peripheral artery disease	–	0.89	0.63–1.25		1.32	0.99–1.77
Probable dementia	Decreased	2.05	1.21–3.48		1.49	0.83–2.66
Abbreviations: CEs = conjugated estrogens. MPA = medroxyprogesterone acetate. p.o. = per oral. HR = hazard ratio. AR = attributable risk. PYs = person–years. CI = confidence interval. Notes: Sample sizes (n) include placebo recipients, which were about half of patients. "Global index" is defined for each woman as the time to earliest diagnosis for coronary heart disease, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer (estrogen plus progestogen group only), hip fractures, and death from other causes. Sources: See template.

Androgenic or antiandrogenic effects

Lipid changes

High doses of CPA have been found to decrease levels of HDL ("good") cholesterol. ^{[199] [200]} Unfavorable blood lipid profile changes are a potential risk factor for cardiovascular disease like atherosclerosis or coronary heart disease. ^[201] CPA has weak androgenic effects in the liver, which may be responsible for its adverse influence on the lipid profile. ^{[202] [203] [200]} Unfavorable lipid changes have also been seen with other antiandrogens, for instance spironolactone ^{[204] [205]} and bicalutamide, ^{[206] [207]} and with androgenic medications. ^{[159] [208] [209]}

The Women's Health Initiative randomized controlled trials demonstrated a significantly increased risk of coronary heart disease with 0.625 mg/day conjugated estrogens and 2.5 mg/day medroxyprogesterone acetate (a progestin closely related to CPA) for menopausal hormone therapy relative to 0.625 mg/day conjugated estrogens alone and placebo in peri- and postmenopausal women. ^{[186] [187]} Whether or not estrogen plus low-dose CPA alone has similar risks has not been studied and hence is unknown. ^{[208] [209]} Biomarker research suggests that the lower androgenic activity of CPA and reduced unfavorable effects on blood lipids may confer less or no coronary heart disease risk, but this has yet to be evaluated in clinical studies. ^{[208] [209]}

Other side effects

Liver toxicity

Incidences of elevated liver enzymes with different dosages of cyproterone acetate in 1,685 healthy males and females of all ages in a large active surveillance study.

The most serious potential side effect of CPA is hepatotoxicity. ^[210] A variety of manifestations of liver disease in association with CPA treatment have been documented, including immunoallergic cytotoxic reactions, cholestasis, autoimmune hepatitis, acute hepatitis, fulminant liver failure, and cirrhosis, as well as an increased risk of hepatocellular carcinoma. ^{[211] [212]} Clinical features may include jaundice, fatigue, nausea, elevated liver enzymes, hepatic necrosis and inflammation, and features of hepatic decompensation. ^[212] Hepatotoxicity due to CPA therapy is most common in elderly patients who are treated with high dosages of the drug for prolonged periods of time, but has also occurred in younger patients. ^[211] The hepatotoxicity of CPA is related to its C1α,2α methylene group. ^[80]

In an uncontrolled open-label active surveillance study of 1,685 healthy males and females of all ages (3 to 75 years for the full sample of 2,506 individuals) treated with CPA for an average of 6.7 years (but in 602 individuals for up to more than 10 years), elevated liver enzymes were seen in 2.6 to 3.1% of individuals at a dosage of 1 to 20 mg/day, in 8.1% of individuals at a dosage of 20 to 50 mg/day, in 10.2% of individuals at a dosage of 50 to 100 mg/day, and in 11.1 to 25.0% of individuals at a dosage of greater than 100 mg/day (up to more than 200 mg/day). ^{[20] [210] [211] [212]} In a trial of 89 men with prostate cancer who received 50 mg/day CPA for 4 years, elevated liver enzymes occurred in 28.2%. ^{[212] [213]} A study of 105 patients treated with 150 mg/day CPA reported a hepatotoxicity rate of 9.5%, with serious liver injury occurring in 3.8% (4/105). ^[212] A study of 303 transgender women treated with high-dose estrogen and 100 mg/day CPA reported an incidence of elevated liver enzymes of 7.2% (22/303). ^[63]

In 2002, it was reported that there were 18 published case reports of CPA-associated hepatitis in the literature, with 6 of these cases resulting in death. ^[210] In addition however, a 1995 publication by the United Kingdom Medicines Control Agency/Committee on Safety of Medicines in its journal Current Problems in Pharmacovigilance described an additional 96 spontaneous reports of hepatotoxicity (91 males, 5 females), with 33 of these cases resulting in death. ^{[214] [215] [210]} The manifestations of hepatotoxicity described in this publication included hepatitis, cholestatic jaundice, and liver failure. ^{[214] [215]} The majority of cases were men being treated with very high doses of CPA (300 mg/day) for prostate cancer. ^{[214] [215]} A 2014 review found that 9 cases specifically of CPA-induced fulminant (sudden-onset and severe) liver failure had been reported to date, with only one of these cases not being fatal. ^[212] As such, the prognosis of CPA-induced liver failure is death. ^[212] However, serious hepatotoxicity occurs mostly in prostate cancer patients who take very high doses of CPA, and serious liver toxicity has not been reported in transgender women. ^[216] All 14 reported cases of serious hepatotoxicity (acute liver failure and acute hepatitis) with CPA described in the 2014 review were in a dosage range of 100 to 300 mg/day and were in elderly men with prostate cancer (age range 65 to 92 years). ^[211] A 2015 publication reported an additional 22 new cases of hepatotoxicity in association with CPA, including one case at 50 mg/day. ^[217]

The risk of hepatotoxicity and death associated with CPA treatment is reportedly the reason that CPA has not been approved by the FDA for use in the United States. ^[218] Patients being treated with high-dose CPA should be closely monitored with liver function tests. ^[219] The risk is dose-dependent, and the low doses of CPA used in birth control pills (2 mg) have been said to represent a non-significant risk. ^[220] However, a German woman who had been taking Diane-35 (containing 2 mg/day CPA) for contraception for 14 years died of liver cancer, and this led to a safety review by drug regulators and the eventual restriction of CPA throughout Europe for the indication of acne treatment in women. ^[158] In any case, liver toxicity with CPA occurs mostly in prostate cancer patients who take very high doses of the medication (200–300 mg/day), and liver toxicity has not been reported in cisgender or transgender women, who usually take lower doses (25–100 mg/day). ^{[211] [216] [6] [7]} However, in 2021, a case report of liver failure and death with 25 mg/day CPA in a young cisgender woman taking it for treatment of hirsutism was published. ^[221]

The hepatotoxicity of the nonsteroidal antiandrogen flutamide is greater than that of CPA. ^{[16] [222]} In a randomized controlled trial and direct head-to-head comparison for prostate cancer, overall rates of liver function deterioration were 9.9% in the 750 mg/day flutamide group (n = 151) and 5.3% in the 300 mg/day oral CPA group (n = 152) (p = 0.128), while liver toxicity requiring discontinuation occurred in 8.6% (13 of 151) in the flutamide group and 2.0% (3 of 152) in the CPA group. ^[16] Findings were similar in another randomized controlled trial and direct head-to-head comparison of 750 mg/day flutamide and 150 mg/day oral CPA; the rates of hepatotoxicity were 15.3% (19 of 124) for flutamide and 9.5% (10 of 105) for CPA (p = 0.034) and the rates of serious hepatotoxicity were 4.8% (6 of 124) for flutamide and 3.8% (4 of 105) for CPA. ^[222] A 2004 review cited 46 published cases of hepatotoxicity in association with flutamide, 21 cases with CPA, 4 cases with nilutamide, and 1 case with bicalutamide, all between 1986 and 2003. ^{[223] [224]} It should be noted however that some of these antiandrogens, like nilutamide and bicalutamide, were introduced after 1986 and hence were launched more recently than the others. ^[223]

There are case reports of suspected cross-hepatotoxicity between CPA and flutamide. ^{[225] [226]} As such, CPA and flutamide may be cross-reactive in terms of hepatotoxicity. ^[227] The hepatotoxicity of CPA may be dependent on age, with greater risk in older people. ^[217]

• v
• t
• e

Published case reports of cyproterone acetate-associated liver toxicity

#	Sex	Age	Dosage	Type	Onset	Outcome	Survivala	Ref	Link
1	Female	73 years	400 mg/day	AH	2.5 months	Survived	N/A	Meijers et al. (1986)	[228]
2	Female	85 years	200 mg/day	AH	4.8 months	Survived	N/A	Meijers et al. (1986)	[228]
3	Male	78 years	200 mg/day	ALF	6 months	Death	2 weeks	Lévesque et al. (1989)	[229]
4	Male	71 years	300 mg/day	AH	5.3 months	Survived	N/A	Blake et al. (1990)	[230]
5	Male	79 years	200–300 mg/day	AH	2.5 months	Survived	N/A	Dore et al. (1990)	[231]
6	Male	80 years	200 mg/day	ALF	7 months	Death	~1–2 months	Antoni et al. (1991)	[232]
7	Male	75 years	300 mg/day	HCC	1.5 years	ND	ND	Ohri et al. (1991)	[233]
8	Male	72 years	300 mg/day	ALF	ND	Survived	N/A	Parys et al. (1991)	[234]
9	Male	65 years	300 mg/day	ALF	1 year	Death	1.6 months	Parys et al. (1991)	[234]
10	Male	83 years	300 mg/day	ALF	1.25 years	Death	2 weeks	Parys et al. (1991)	[234]
11	Male	78 years	150 mg/day	AH	~3 months	Survived	N/A	Drakos et al. (1992)	[235]
12	Female	24 years	100 mg/day (RS)	CH	3 months	Survived	N/A	Hassler et al. (1992)	[236]
13	Male	74 years	200 mg/day	AH	11 months	Survived	N/A	Roila et al. (1993)	[237]
14	Male	79 years	300 mg/day	ALF	10 months	Death	2 weeks	Bressollette et al. (1994)	[238]
15	Male	92 years	100 mg/day	ALF	4 months	Death	5 weeks	Hirsch et al. (1994)	[239]
16	Male	65 years	600 mg/day	HCC	4 months	Survived	N/A	Kattan et al. (1994)	[240]
17	Female	22 years	100–250 mg/day	HCC	10 years	Death	9 months	Watanabe et al. (1994)	[241] [242]
18	Female	19 years	200–300 mg/day	HCC	9 years	Survived	N/A	Watanabe et al. (1994)	[241] [242]
19	Female	19 years	200 mg/day	HCC	~10 years	Survived	N/A	Watanabe et al. (1994)	[241] [242]
20	Male	87 years	200 mg/day	ALF	4 months	Death	~3.5 weeks	Pinganaud et al. (1995)	[243]
21	Male	78 years	150 mg/day	ALF	1 year	Death	3 weeks	Pinganaud et al. (1995)	[243]
22	Female	45 years	2 mg/day (BCP)	HCC	14 years	Death	9 months	Rüdiger et al. (1995)	[244]
23	Male	78 years	200–300 mg/day	ALF	3 months	Death	9 months	Castellani et al. (1996)	[245]
24	Male	73 years	300 mg/day	ALF	4 months	Survived	N/A	Murphy et al. (1996)	[246]
25	Male	64 years	100 mg/day	AH	6 months	Survived	N/A	Ruiz-Rebollo et al. (1997)	[247]
26	Female	≥8 years	200–300 mg/day	HCC	>4 years	Survived	N/A	Watanabe et al. (1997)	[242]
27	Male	21 years	100–350 mg/day	HCC	15 years	Survived	N/A	Watanabe et al. (1997)	[242]
28	Male	84 years	ND	ALF	ND	Death	1 week	Lombardi et al. (1998)	[248]
29	Male	81 years	300 mg/day	ALF	6 months	Death	1.6 months	Friedman et al. (1999)	[249]
30	Male	66 years	300 mg/day	ALF	2 months	Death	4 weeks	Friedman et al. (1999)	[249]
31	Male	14 years	100 mg/day	Cirrhosis	~7.5 years	Death	~1 year	Garty et al. (1999)	[250]
32	Male	84 years	100–300 mg/day	HCC	10 years	Death	6 days	Manfredi et al. (2000)	[251]
33	Male	87 years	300 mg/day	AH	ND	Survived	N/A	Giordano et al. (2001)	[252]
34	Female	17 years	2 mg/day (BCP)	AIH/cirrhosis	2 months	Survived	N/A	Kacar et al. (2002)	[253]
35	Male	76 years	150 mg/day	AH	7 months	Survived	N/A	Manolakopoulos et al. (2004)	[226]
36	Male	78 years	200 mg/day	ALF	3 months	Death	1.0 months	Famularo et al. (2005)	[254]
37	Male	82 years	200 mg/day	AH	12 months	Survived	N/A	Savidou et al. (2006)	[255]
38	Male	83 years	300 mg/day	AH	7 months	Death	1.4 months	Savidou et al. (2006)	[255]
39	Male	78 years	300 mg/day	AH	3 months	Survived	N/A	Savidou et al. (2006)	[255]
40	Male	78 years	150 mg/day	ALF	2 months	Survived	N/A	Miquel et al. (2007)	[225]
41b	Female	22 years	2 mg/day (BCP)	BCS	7 days	ND	ND	He et al. (2009)	[256] [257]
42	Male	89 years	150–300 mg/day	ALF	3.2 months	Death	28 days	Kim et al. (2009)	[258]
43	Male	71 years	100–200 mg/day	ALF	2–3 months	Death	20 days	Hsu et al. (2011)	[259]
44	Male	66 years	200 mg/day	AH/cirrhosis	4 months	Survived	N/A	Abenavoli et al. (2013)	[260]
45	Male	75 years	200 mg/day	ALF	9 months	Survived	N/A	Vodička et al. (2013)	[261]
46	Male	87 years	200 mg/day	ALF	6 months	Death	20 days	Kim et al. (2014)	[211]
47	Male	80 years	150 mg/day	AH	4.0 months	Survived	N/A	Bessone et al. (2016)	[217]
48	Male	73 years	200 mg/day	AH	2.1 months	Survived	N/A	Bessone et al. (2016)	[217]
49	Male	54 years	200 mg/day	AIH	4.0 months	Survived	N/A	Bessone et al. (2016)	[217]
50	Male	60 years	200 mg/day	AH	1.1 months	Survived	N/A	Bessone et al. (2016)	[217]
51	Male	74 years	200 mg/day	AH	5.1 months	Survived	N/A	Bessone et al. (2016)	[217]
52	Male	66 years	150 mg/day	ALF	3.2 months	Death	ND	Bessone et al. (2016)	[217]
53	Male	77 years	100 mg/day	AH	8.1 months	Survived	N/A	Bessone et al. (2016)	[217]
54	Male	72 years	200 mg/day	AH	5.0 months	Survived	N/A	Bessone et al. (2016)	[217]
55	Male	80 years	200 mg/day	AH	1.9 months	Survived	N/A	Bessone et al. (2016)	[217]
56	Male	69 years	100 mg/day	AH	4.1 months	Survived	N/A	Bessone et al. (2016)	[217]
57	Male	58 years	200 mg/day	AH	10.1 months	Survived	N/A	Bessone et al. (2016)	[217]
58	Male	83 years	100 mg/day	AH	2.1 months	Survived	N/A	Bessone et al. (2016)	[217]
59	Male	75 years	200 mg/day	AH	4.9 months	Survived	N/A	Bessone et al. (2016)	[217]
60	Male	72 years	100 mg/day	AH	8.0 months	Survived	N/A	Bessone et al. (2016)	[217]
61	Male	72 years	50 mg/day	AH	5.9 months	Survived	N/A	Bessone et al. (2016)	[217]
62	Male	66 years	100 mg/day	AH/CH	1.2 years	Survived	N/A	Bessone et al. (2016)	[217]
63	Male	58 years	200 mg/day	ALF	5.0 months	Death	ND	Bessone et al. (2016)	[217]
64	Male	75 years	200 mg/day	ALF	7.9 months	Death	ND	Bessone et al. (2016)	[217]
65	Male	74 years	150 mg/day	AH	9.9 months	Survived	N/A	Bessone et al. (2016)	[217]
66	Male	64 years	100 mg/day	AH	3.3 months	Survived	N/A	Bessone et al. (2016)	[217]
67	Male	64 years	150 mg/day	AH/CH	4.9 months	Survived	N/A	Bessone et al. (2016)	[217]
68	Male	64 years	150 mg/day	AH/cirrhosis	4.9 months	Survived	N/A	Bessone et al. (2016)	[217]
69	Male	61 years	300 mg/day	ALF	3 months	Death	2.6 months	Nour et al. (2017)	[262]
70	Female	30 years	25 mg/day	ALF	6 months	Death	4 days	Kumar et al. (2021)	[221]
Abbreviations: BCP = Birth control pill. RS = Reverse sequential (days 5–25 of cycle). ALF = Acute liver failure (fulminant liver failure). AH = Acute hepatitis. CH = Cholestatic hepatitis. AIH = Autoimmune hepatitis. HCC = Hepatocellular carcinoma. BCS = Budd–Chiari syndrome. ND = No data. N/A = Not applicable. Footnotes:a = Time until death after onset of liver toxicity. b = Probably related to ethinylestradiol rather than to cyproterone acetate. [256] Notes: Many additional cases have been described in spontaneous adverse drug reaction reporting systems of individual countries. These include 19 cases (5 deaths) by late 1988 [230] and 96 cases (91 males, 5 females; 33 deaths) by early 1995 in the United Kingdom; [214] [215] 32 cases (deaths not given) in Australia by 2004; [263] and 15 cases (no deaths) in Spain by 2006. [264] The cases from Bessone et al. (2016) were reported between 1993 and 2013 and were from Spanish and Latin American drug-induced liver injury databases (17 cases in Argentina, 2 cases in Uruguay, 3 cases in Spain). [217] Worldwide, 153 cases of liver abnormalities were reported to Schering, the manufacturer, between 1982 and 1987. [230] In a large observational study of 2,506 patients, Heinemann et al. (1997) reported 7 cases of benign liver tumors and no cases of serious liver toxicity or HCC. [20] Large observational studies have found no increased risk of liver toxicity or HCC with cyproterone acetate at BCP doses. [20] [265] [266] A fatal case of ALF in a common chimpanzee has also been reported. [267] Sources: [255] [223] [249]

Vitamin B12 deficiency

Both low-dose (2 mg/day) and high-dose CPA combined with an estrogen have been associated with vitamin B12 deficiency in women in some small studies. ^{[268] [269] [7]} Vitamin B12 deficiency in turn has been associated with depression, anxiety, irritability, and fatigue due to depletion of central monoamine neurotransmitters. ^{[270] [271]} For this reason, it has been suggested that low vitamin B12 levels might be involved in the side effect of depression that has sometimes been associated with CPA. ^[24] Serum vitamin B12 monitoring and supplementation (e.g., 100 to 200 μg/day orally) as necessary may be recommended during CPA therapy. ^{[7] [268] [269]}

Miscellaneous

CPA has been associated rarely with retinal vascular disorder, retinal vein thrombosis, and optic neuritis. ^[272] A case report of symptomatic epidural lipomatosis in association with CPA therapy has been published. ^[273] A published case report of lymphocytic pneumonitis in associated with CPA also exists. ^[4] There is a case report of severe stretch marks in association with CPA therapy. ^[274]

Dosage dependence

Belisle and Love (1986) directly compared Diane (ethinylestradiol 50 μg/day and CPA 2 mg/day) alone versus the combination of Diane and CPA 100 mg/day (Androcur) in 158 women with hirsutism. ^[5] They reported no differences in mean incidences of side effects including menometrorrhagia (9.9%), acne (6.5%), decreased libido (9.5%), edema (9.3%), nausea (17.5%), vomiting (4.8%), headache (20.3%), and depression (12.7%). ^[5] Conversely, the incidences of fatigue and amenorrhea were significantly greater in the Diane plus Androcur group relative to the Diane alone group (6.7% vs. 2.5% and 5.4–32.6% vs. 0–4.2%, respectively), the incidence of breast tenderness was significantly lower in the Diane plus Androcur group than in the Diane alone group (3.6–26.3% vs. 12.5–46.4%), and the percent gain in body weight relative to baseline was significantly greater in the Diane plus Androcur group than in the Diane alone group (6.3% vs. 1.1% at 12 months). ^[5]

CPA at relatively low doses, for instance 10–20 mg/day, has been reported in small studies to cause few to no side effects in men. ^[275] Conversely, CPA at higher doses, for instance 100 mg/day or greater, has been reported to produce a variety of side effects in men including decreased libido, erectile dysfunction, gynecomastia, tiredness, weakness, decreased efficiency, weight gain, skin dryness, skin peeling, and decreased body hair (e.g., trunk and pubic region). ^[275]

• v
• t
• e

Side effects of estrogen plus high- versus low-dose cyproterone acetate in women

Side effect	High-dose [c] (n = 602) (%)	Low-dose [d] (n = 226) (%)
Fatigue	22.0	13.0
Weight gain (>2 kg or >4.4 lbs)	18.5	5.5
Decreased libido	10.0	6.0
Breast discomfort	9.2	15.0
Nausea	9.0	3.9
Headaches	7.3	10.4
Depression	5.1	2.0
Irregular uterine bleeding	3.5	7.2
Sleep disturbance	3.5	–
Thrombophlebitis	1.0	3.0
Chloasma	0.9	–
Constipation	0.5	–
Thrombosis	0.15	0.9
Heavy legs or cramps	–	4.6
Footnotes: Average dosage; range less than 10 mg/day to >200 mg/day. Liver enzymes monitored in 1,685 individuals, including 1,131 males and 554 females. Reverse sequential regimen: In women with hirsutism, cyproterone acetate 100 mg/day from days 5 to 14 of the menstrual cycle and ethinylestradiol 50 μg/day from days 5 to 25 of the cycle. Diane: In women with hirsutism, cyproterone acetate 2 mg/day and ethinylestradiol 50 μg/day from days 5 to 25 of the cycle. Sources: See template.

Withdrawal

Adrenal insufficiency

Abrupt withdrawal of CPA can be harmful, and the package insert from Schering AG recommends the daily dose be reduced by no more than 50 mg at intervals of several weeks. The concern is the manner in which CPA affects the adrenal glands. Due to its glucocorticoid activity, high levels of CPA may reduce ACTH, resulting in adrenal insufficiency if discontinued abruptly. In addition, although CPA reduces androgen production in the gonads, it can increase the production of adrenal androgens, in some cases resulting in an overall rise in testosterone levels. ^[276] Thus, the sudden withdrawal of CPA could result in undesirable androgenic effects.^{[ citation needed ]} This is a particular concern because androgens, especially DHT, suppress adrenal function, further reducing corticosteroid production. ^[277]

Suppression of adrenal function and reduced response to adrenocorticotropic hormone (ACTH) have been reported with CPA treatment. As a result, adrenal insufficiency and hence low cortisol and aldosterone levels and ACTH responsiveness can occur upon discontinuation of CPA. Low aldosterone levels may lead to hyponatremia (sodium loss) and hyperkalemia (excess potassium). Patients taking CPA should have their cortisol levels and electrolytes monitored, and if hyperkalemia develops, should reduce the consumption of foods with high potassium content or discontinue the medication.

References

1. Bachelot A, Chabbert-Buffet N, Salenave S, Kerlan V, Galand-Portier MB (February 2010). "Anti-androgen treatments". Ann. Endocrinol. (Paris). 71 (1): 19–24. doi:10.1016/j.ando.2009.12.001. PMID   20096826.
2. Burton JL (December 1979). "Anti-androgen therapy in dermatology: a review". Clin. Exp. Dermatol. 4 (4): 501–7. doi:10.1111/j.1365-2230.1979.tb01648.x. PMID   394887. S2CID   29236094.
3. Hammerstein, J. (1990). "Antiandrogens: Clinical Aspects". Hair and Hair Diseases. pp. 827–886. doi:10.1007/978-3-642-74612-3_35. ISBN   978-3-642-74614-7.
4. Rittmaster RS (June 1999). "Antiandrogen treatment of polycystic ovary syndrome". Endocrinol. Metab. Clin. North Am. 28 (2): 409–21. doi:10.1016/S0889-8529(05)70077-3. PMID   10352926.
5. Belisle S, Love EJ (December 1986). "Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study". Fertil. Steril. 46 (6): 1015–20. doi: 10.1016/S0015-0282(16)49873-0 . PMID   2946604.
6. Diamanti-Kandarakis E (October 1998). "How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?". J. Endocrinol. Invest. 21 (9): 623–9. doi:10.1007/BF03350788. PMID   9856417. S2CID   46484837.
7. Diamanti-Kandarakis E (September 1999). "Current aspects of antiandrogen therapy in women". Curr. Pharm. Des. 5 (9): 707–23. doi:10.2174/1381612805666230111201150. PMID   10495361.
8. Guay DR (January 2009). "Drug treatment of paraphilic and nonparaphilic sexual disorders". Clin Ther. 31 (1): 1–31. doi:10.1016/j.clinthera.2009.01.009. PMID   19243704. No quantitative data on these adverse events are available, even in the product prescribing information and data sheets.
9. Migliari R, Muscas G, Murru M, Verdacchi T, De Benedetto G, De Angelis M (1999). "Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy". Archivio Italiano di Urologia e Andrologia. 71 (5): 293–302. PMID   10673793. The only advantage of cyproterone acetate on pure antiandrogens seems to be the low incidence of hot flushes; [...] However, hepatotoxicity associated with long term daily doses of 300 mg daily and the unacceptably high incidence of cardiovascular side effects (10%) should restrict its use to patients who are intolerant of pure antiandrogen compound. In contrast to steroidal compound nonsteroidal compounds let sexual potency to be retained, [...]
10. Sarah H. Wakelin (1 June 2002). Systemic Drug Treatment in Dermatology: A Handbook. CRC Press. p. 32. ISBN   978-1-84076-013-2.
11. Gräf, K.-J.; Brotherton, J.; Neumann, F. (1974). "Clinical Uses of Antiandrogens". Androgens II and Antiandrogens / Androgene II und Antiandrogene. pp. 485–542. doi:10.1007/978-3-642-80859-3_7. ISBN   978-3-642-80861-6.
12. Iversen P, Melezinek I, Schmidt A (January 2001). "Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function". BJU International. 87 (1): 47–56. doi: 10.1046/j.1464-410x.2001.00988.x . PMID   11121992.
13. Terrence Priestman (26 May 2012). Cancer Chemotherapy in Clinical Practice. Springer Science & Business Media. pp. 97–. ISBN   978-0-85729-727-3.
14. Di Lorenzo G, Autorino R, Perdonà S, De Placido S (2005). "Management of gynaecomastia in patients with prostate cancer: a systematic review". Lancet Oncol. 6 (12): 972–9. doi:10.1016/S1470-2045(05)70464-2. PMID   16321765.
15. Hirawat S, Budman DR, Kreis W (June 2003). "The androgen receptor: structure, mutations, and antiandrogens". Cancer Invest. 21 (3): 400–17. doi:10.1081/CNV-120018232. PMID   12901287. S2CID   25252639.
16. Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven RF, Debois M, Collette L (April 2004). "Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892". Eur. Urol. 45 (4): 457–64. doi:10.1016/j.eururo.2003.11.016. PMID   15041109.
17. Fourcade, R.-O.; McLeod, D. (March 2004). "Tolerability of Antiandrogens in the Treatment of Prostate Cancer". UroOncology. 4 (1): 5–13. doi:10.1080/1561095042000191655. ISSN   1561-0950. Although during CPA therapy the activity of androgens at the breast is blocked, thereby leading to unopposed oestrogenic stimulation at the breast, circulating oestrogen levels decline due to the reduction in the levels of circulating androgens available for aromatisation and also the decrease in serum LH levels. CPA is therefore associated with a relatively low incidence of gynaecomastia (4-9%) [14,29,30].
18. Shiffman, Melvin A. (2012). "Cellulite: Etiology, Classification, Pathology, and Treatment". Aesthetic Medicine. pp. 265–272. doi:10.1007/978-3-642-20113-4_25. ISBN   978-3-642-20112-7.
19. "Mylan-Cyproterone Label" (PDF).
20. Heinemann LA, Will-Shahab L, van Kesteren P, Gooren LJ (May 1997). "Safety of cyproterone acetate: report of active surveillance". Pharmacoepidemiol Drug Saf. 6 (3): 169–78. doi:10.1002/(SICI)1099-1557(199705)6:3<169::AID-PDS263>3.0.CO;2-3. PMID   15073785. S2CID   24781052.
21. "Androcur Label" (PDF).
22. James Barrett (2007). Transsexual and Other Disorders of Gender Identity: A Practical Guide to Management. Radcliffe Publishing. p. 174. ISBN   978-1-85775-719-4.
23. Barth JH, Cherry CA, Wojnarowska F, Dawber RP (July 1991). "Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study". Clinical Endocrinology. 35 (1): 5–10. doi:10.1111/j.1365-2265.1991.tb03489.x. PMID   1832346. S2CID   27293697.
24. Rushton DH (July 2002). "Nutritional factors and hair loss". Clin. Exp. Dermatol. 27 (5): 396–404. doi:10.1046/j.1365-2230.2002.01076.x. PMID   12190640. S2CID   39327815.
25. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson C, Watson RB, Gardiner RA (September 2002). "Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial" (PDF). BJU Int. 90 (4): 427–32. doi:10.1046/j.1464-410X.2002.02917.x. hdl: 10072/16905 . PMID   12175403. S2CID   22941006.
26. Kaisary AV (2005). "Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer". Prostate Cancer Prostatic Dis. 8 (2): 140–51. doi:10.1038/sj.pcan.4500800. PMID   15852051.
27. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson CE, Watson RB, Gardiner RA (May 2004). "Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial". BJU Int. 93 (7): 975–9. doi:10.1111/j.1464-410X.2004.04763.x. hdl: 10072/16906 . PMID   15142146. S2CID   22391314.
28. Seal LJ, Franklin S, Richards C, Shishkareva A, Sinclaire C, Barrett J (December 2012). "Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens". The Journal of Clinical Endocrinology and Metabolism. 97 (12): 442–8. doi: 10.1210/jc.2012-2030 . PMID   23055547.
29. Gava G, Cerpolini S, Martelli V, Battista G, Seracchioli R, Meriggiola MC (August 2016). "Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness". Clin. Endocrinol. (Oxf). 85 (2): 239–46. doi:10.1111/cen.13050. PMID   26932202. S2CID   30150360.
30. Colizzi M, Costa R, Todarello O (January 2014). "Transsexual patients' psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: results from a longitudinal study". Psychoneuroendocrinology. 39: 65–73. doi:10.1016/j.psyneuen.2013.09.029. PMID   24275005. S2CID   29369675.
31. Fisher AD, Castellini G, Ristori J, Casale H, Cassioli E, Sensi C, Fanni E, Amato AM, Bettini E, Mosconi M, Dèttore D, Ricca V, Maggi M (November 2016). "Cross-Sex Hormone Treatment and Psychobiological Changes in Transsexual Persons: Two-Year Follow-Up Data" (PDF). J. Clin. Endocrinol. Metab. 101 (11): 4260–4269. doi: 10.1210/jc.2016-1276 . PMID   27700538.
32. Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–92. doi:10.2165/00003495-200363050-00003. PMID   12600226. S2CID   28436828.
33. Seaman HE, Snowball J, de Vries CS (2006). "Cyproterone Acetate + Ethinyloestradiol and the Risk of Depression". Pharmacoepidemiology and Drug Safety. 15 (S1): S25. doi:10.1002/pds.1295. ISSN   1053-8569. PMID   16986216. S2CID   3586619.
34. Husmann, Friedrich (1997). "Clinical Experiences with a Combination of Estradiol Valerate and Cyproterone Acetate for Hormone Replacement". Women's Health and Menopause. Medical Science Symposia Series. Vol. 11. pp. 257–261. doi:10.1007/978-94-011-5560-1_38. ISBN   978-94-010-6343-2. ISSN   0928-9550.
35. Waken SH, Maibach HI, Archer CB (21 May 2015). Handbook of Systemic Drug Treatment in Dermatology (Second ed.). CRC Press. pp. 34–. ISBN   978-1-4822-2286-9.
36. Giltay EJ, Gooren LJ (2009). "Potential side effects of androgen deprivation treatment in sex offenders". J. Am. Acad. Psychiatry Law. 37 (1): 53–8. PMID   19297634.
37. Briken P, Hill A, Berner W (August 2003). "Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review". J Clin Psychiatry. 64 (8): 890–7. doi:10.4088/JCP.v64n0806. PMID   12927003.
38. Wibowo E, Schellhammer P, Wassersug RJ (January 2011). "Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy". J. Urol. 185 (1): 17–23. doi:10.1016/j.juro.2010.08.094. PMID   21074215.
39. Jagielska, Beata; Poniatowska, Grażyna; Tałasiewicz, Konrad; Demkow, Tomasz; Wiechno, Paweł (2017). "Systemic complications in the hormonal treatment of prostate and breast cancer". Nowotwory. Journal of Oncology. 67 (3): 206–214. doi: 10.5603/NJO.2017.0034 . ISSN   2300-2115.
40. Grasswick LJ, Bradford JM (July 2003). "Osteoporosis associated with the treatment of paraphilias: a clinical review of seven case reports". J. Forensic Sci. 48 (4): 849–55. doi:10.1520/JFS2002089. PMID   12877306.
41. Lindsay R (1999). "The lack of effect of progestogen on bone". J Reprod Med. 44 (2 Suppl): 215–20. PMID   11392035.
42. Khalil R, Antonio L, Laurent MR, David K, Kim NR, Evenepoel P, Eisenhauer A, Heuser A, Cavalier E, Khosla S, Claessens F, Vanderschueren D, Decallonne B (August 2020). "Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study" (PDF). Eur J Endocrinol. 183 (2): 181–189. doi:10.1530/EJE-20-0348. PMID   32454455. S2CID   218910292.
43. Curtis, Kathryn M.; Martins, Summer L. (2006). "Progestogen-only contraception and bone mineral density: a systematic review". Contraception. 73 (5): 470–487. doi:10.1016/j.contraception.2005.12.010. ISSN   0010-7824. PMID   16627031.
44. Sarfati, Julie; de Vernejoul, Marie-Christine (2009). "Impact of combined and progestogen-only contraceptives on bone mineral density". Joint Bone Spine. 76 (2): 134–138. doi:10.1016/j.jbspin.2008.09.014. ISSN   1297-319X. PMID   19181558.
45. Nelson ER, Wardell SE, McDonnell DP (March 2013). "The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis". Bone. 53 (1): 42–50. doi:10.1016/j.bone.2012.11.011. PMC   3552054 . PMID   23168292.
46. Spona J, Lunglmayr G (July 1980). "Prolaktin-Serumspiegel unter Behandlung des Prostatakarzinoms mit Östradiol-17 beta-undezylat und Cyproteronazetat" [Serum Prolactin Levels During Therapy of Prostatic Cancer with Estradiol-17 beta-undecylate and Cyproterone Acetate]. Wiener Klinische Wochenschrift (in German). 92 (14): 494–497. ISSN   0043-5325. PMID   6933738.
     •Lunglmayr G, Spona J (1981). "Prolaktin-Serumspiegel unter Behandlung des Prostatakarzinoms mit Östradiol-17 beta-undezylat und Cyproteronazetat". Verhandlungsbericht der Deutschen Gesellschaft für Urologie (in German). Vol. 32. Berlin, Heidelberg: Springer. pp. 413–415. doi:10.1007/978-3-642-81706-9_120. ISBN   978-3-540-11017-0.
47. Schürmeyer, Th.; Graff, J.; Senge, Th.; Nieschlag, E. (1986). "Effect of oestrogen or cyproterone acetate treatment on adrenocortical function in prostate carcinoma patients". Acta Endocrinologica. 111 (3): 360–367. doi:10.1530/acta.0.1110360. ISSN   0804-4643. PMID   2421511.
48. Holub, G.; Lunglmayr, G.; Spona, J. (1981). "Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer". Urological Research. 9 (5): 245–7. doi:10.1007/BF00256895. ISSN   0300-5623. PMID   6458145. S2CID   9312796.
49. Rost, A.; Schmidt-Gollwitzer, M.; Hantelmann, W.; Brosig, W. (1981). "Cyproterone acetate, testosterone, LH, FSH, and prolactin levels in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancer". The Prostate. 2 (3): 315–322. doi:10.1002/pros.2990020310. ISSN   0270-4137. PMID   6458025. S2CID   22364184.
50. Jeffcoate, W. J.; Matthews, R. W.; Edwards, C. R. W.; Field, L. H.; Besser, G. M. (1980). "The effect of cyproterone acetate on serum testosterone, LH, FSH, and prolactin in male sexual offenders". Clinical Endocrinology. 13 (2): 189–195. doi:10.1111/j.1365-2265.1980.tb01041.x. ISSN   0300-0664. PMID   6777092. S2CID   10145079.
51. Graf KJ, Schmidtgollwitzer M, Koch UJ, Lorenz F, Hammerstein J (January 1978). "Hyperprolactinemia Induced by Cyproterone Acetate in Human Subjects". Acta Endocrinologica. 87: 96.
52. Bercovich E, Cigno M, Soli M (January 1983). "Serum prolactin levels induced by cyproterone acetate therapy in patients with prostatic carcinoma". Prostate. 4 (4): 425–426.
53. Defreyne J, Nota N, Pereira C, Schreiner T, Fisher AD, den Heijer M, T'Sjoen G (October 2017). "Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment". LGBT Health. 4 (5): 328–336. doi:10.1089/lgbt.2016.0190. PMID   28880825.
54. Fonzo, Domenico; Angeli, Alberto; Sivieri, Roberto; Andriolo, Salvatore; Frajria, Roberto; Ceresa, Franco (1977). "Hyperprolactinemia in Girls with Idiopathic Precocious Puberty Under Prolonged Treatment with Cyproterone Acetate". The Journal of Clinical Endocrinology & Metabolism. 45 (1): 164–168. doi:10.1210/jcem-45-1-164. ISSN   0021-972X. PMID   874063.
55. Mah, Peak Mann; Webster, Jonathan (2002). "Hyperprolactinemia: Etiology, Diagnosis, and Management". Seminars in Reproductive Medicine. 20 (4): 365–374. doi:10.1055/s-2002-36709. ISSN   1526-8004. PMID   12536359.
56. Gil M, Oliva B, Timoner J, Maciá MA, Bryant V, de Abajo FJ (December 2011). "Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study". Br J Clin Pharmacol. 72 (6): 965–8. doi:10.1111/j.1365-2125.2011.04031.x. PMC   3244644 . PMID   21627676.
57. Williams, Robert F.; Gianfortoni, Joseph G.; Hodgen, Gary D. (1985). "Hyperprolactinemia Induced by an Estrogen- Progesterone Synergy: Quantitative and Temporal Effects of Estrogen Priming in Monkeys". The Journal of Clinical Endocrinology & Metabolism. 60 (1): 126–132. doi:10.1210/jcem-60-1-126. ISSN   0021-972X. PMID   3964786.
58. Williams, Robert F.; Barber, Donald L.; Cowan, Bryan D.; Lynch, Almorris; Marut, Edward L.; Hodgen, Gary D. (1981). "Hyperprolactinemia in monkeys: Induction by an estrogen-progesterone synergy". Steroids. 38 (3): 321–331. doi:10.1016/0039-128X(81)90067-2. ISSN   0039-128X. PMID   7303037. S2CID   25845876.
59. Moltz, L.; Römmler, A.; Post, K.; Schwartz, U.; Hammerstein, J. (1980). "Medium dose cyproterone acetate (CPA): Effects on hormone secretion and on spermatogenesis in men". Contraception. 21 (4): 393–413. doi:10.1016/S0010-7824(80)80017-5. ISSN   0010-7824. PMID   6771095.
60. Moltz, L.; Römmler, A.; Schwartz, U.; Post, K.; Hammerstein, J. (1978). "252. Cyproterone acetate (CPA)-a potential male contraceptive: further studies on the interactions with endocrine parameters". Journal of Steroid Biochemistry. 9 (9): 865. doi:10.1016/0022-4731(78)90952-4. ISSN   0022-4731.
61. Moltz, L.; Römmler, A.; Schwartz, U.; Hammerstein, J. (1978). "Effects of Cyproterone Acetate (CPA) on Pituitary Gonadotrophin Release and on Androgen Secretion Before and After LH-RH Double Stimulation Tests in Men". International Journal of Andrology. 1 (s2b): 713–719. doi: 10.1111/j.1365-2605.1978.tb00518.x . ISSN   0105-6263.
62. Meriggiola, M. C.; Costantino, A.; Cerpolini, S.; Bremner, W. J.; Huebler, D.; Morselli-Labate, A. M.; Kirsch, B.; Bertaccini, A.; Pelusi, C.; Pelusi, G. (2003). "Testosterone Undecanoate Maintains Spermatogenic Suppression Induced by Cyproterone Acetate Plus Testosterone Undecanoate in Normal Men". The Journal of Clinical Endocrinology & Metabolism. 88 (12): 5818–5826. doi: 10.1210/jc.2003-030574 . hdl: 1773/4349 . ISSN   0021-972X. PMID   14671175.
63. Asscheman H, Gooren LJ, Eklund PL (September 1989). "Mortality and morbidity in transsexual patients with cross-gender hormone treatment" (PDF). Metab. Clin. Exp. 38 (9): 869–73. doi:10.1016/0026-0495(89)90233-3. PMID   2528051.
64. Asscheman H, Gooren LJ, Assies J, Smits JP, de Slegte R (June 1988). "Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals". Clin. Endocrinol. (Oxf). 28 (6): 583–8. doi:10.1111/j.1365-2265.1988.tb03849.x. PMID   2978262. S2CID   29214187.
65. Gooren LJ, Harmsen-Louman W, van Kessel H (February 1985). "Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction". Clin. Endocrinol. (Oxf). 22 (2): 201–7. doi:10.1111/j.1365-2265.1985.tb01081.x. PMID   3157511. S2CID   1468511.
66. Capozzi, Anna; Scambia, Giovanni; Pontecorvi, Alfredo; Lello, Stefano (2015). "Hyperprolactinemia: pathophysiology and therapeutic approach". Gynecological Endocrinology. 31 (7): 506–510. doi:10.3109/09513590.2015.1017810. ISSN   0951-3590. PMID   26291795. S2CID   28930221.
67. Naidoo, U.; Goff, D.C.; Klibanski, A. (2003). "Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents". Psychoneuroendocrinology. 28: 97–108. doi:10.1016/S0306-4530(02)00129-4. ISSN   0306-4530. PMID   12650684. S2CID   22543496.
68. Rastrelli, Giulia; Corona, Giovanni; Maggi, Mario (2015). "The role of prolactin in andrology: what is new?". Reviews in Endocrine and Metabolic Disorders. 16 (3): 233–248. doi:10.1007/s11154-015-9322-3. ISSN   1389-9155. PMID   26542707. S2CID   23648256.
69. Buvat, J (2003). "Hyperprolactinemia and sexual function in men: a short review". International Journal of Impotence Research. 15 (5): 373–377. doi:10.1038/sj.ijir.3901043. ISSN   0955-9930. PMID   14562140.
70. Krüger, T (2002). "Orgasm-induced prolactin secretion: feedback control of sexual drive?". Neuroscience & Biobehavioral Reviews. 26 (1): 31–44. doi:10.1016/S0149-7634(01)00036-7. ISSN   0149-7634. PMID   11835982.
71. Verhelst, Johan; Abs, Roger (2003). "Hyperprolactinemia". Treatments in Endocrinology. 2 (1): 23–32. doi:10.2165/00024677-200302010-00003. ISSN   1175-6349. PMID   15871552. S2CID   25676252.
72. La Torre D, Falorni A (2007). "harmacological causes of hyperprolactinemia". Therapeutics and Clinical Risk Management. 3 (5): 929–951. PMC   2376090 . PMID   18473017.
73. Schlatterer K, Yassouridis A, von Werder K, Poland D, Kemper J, Stalla GK (October 1998). "A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients". Arch Sex Behav. 27 (5): 475–92. doi:10.1023/a:1018704630036. PMID   9795728. S2CID   25388581.
74. Bazarra-Castro, M. Á. (2009). Etiological Aspects, Therapy Regimes, Side Effects and Treatment Satisfaction of Transsexual Patients (Doctoral dissertation, LMU München). doi:10.5282/edoc.9984
75. Frawley, L. Stephen; Porter, Tom E.; Kineman, Rhonda D. (1990). "Effects of Prolactin on Target Cells". Neuroendocrine Perspectives. Vol. 8. pp. 39–75. doi:10.1007/978-1-4612-3446-3_2. ISBN   978-1-4612-8014-9. ISSN   0168-0617.
76. Bole-Feysot, Christine; Goffin, Vincent; Edery, Marc; Binart, Nadine; Kelly, Paul A. (1998). "Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice". Endocrine Reviews. 19 (3): 225–268. doi: 10.1210/edrv.19.3.0334 . ISSN   0163-769X. PMID   9626554.
77. Higuchi, Kazumi; Nawata, Hajime; Maki, Toshio; Higashizima, Masayoshi; Kato, Ken-Ichi; Ibayashi, Hiroshi (1984). "Prolactin Has a Direct Effect on Adrenal Androgen Secretion". The Journal of Clinical Endocrinology & Metabolism. 59 (4): 714–718. doi:10.1210/jcem-59-4-714. ISSN   0021-972X. PMID   6090494.
78. Schiebinger, Rick J.; Chrousos, George P.; Culter, Gordon B.; Loriaux, D. Lynn (1986). "The Effect of Serum Prolactin on Plasma Adrenal Androgens and the Production and Metabolic Clearance Rate of Dehydroepiandrosterone Sulfate in Normal and Hyperprolactinemic Subjects". The Journal of Clinical Endocrinology & Metabolism. 62 (1): 202–209. doi:10.1210/jcem-62-1-202. ISSN   0021-972X. PMID   2999177.
79. Langan, Ewan A.; Hinde, Eleanor; Paus, Ralf (2018). "Prolactin as a candidate sebotrop(h)ic hormone?". Experimental Dermatology. 27 (7): 729–736. doi: 10.1111/exd.13545 . ISSN   0906-6705. PMID   29582473.
80. Pucci E, Petraglia F (December 1997). "Treatment of androgen excess in females: yesterday, today and tomorrow". Gynecol. Endocrinol. 11 (6): 411–33. doi:10.3109/09513599709152569. PMID   9476091.
81. Miller JA, Jacobs HS (May 1986). "Treatment of hirsutism and acne with cyproterone acetate". Clin Endocrinol Metab. 15 (2): 373–89. doi:10.1016/S0300-595X(86)80031-7. PMID   2941191.
82. Raj R, Korja M, Koroknay-Pál P, Niemelä M (2018). "Multiple meningiomas in two male-to-female transsexual patients with hormone replacement therapy: A report of two cases and a brief literature review". Surg Neurol Int. 9: 109. doi: 10.4103/sni.sni_22_18 . PMC   5991277 . PMID   29930875.
83. Nota NM, Wiepjes CM, de Blok C, Gooren LJ, Peerdeman SM, Kreukels B, den Heijer M (July 2018). "The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment". Brain. 141 (7): 2047–2054. doi: 10.1093/brain/awy108 . PMID   29688280.
84. J. Larry Jameson; Leslie J. De Groot (25 February 2015). Endocrinology: Adult and Pediatric E-Book. Elsevier Health Sciences. pp. 2293, 2464, 2479, 6225. ISBN   978-0-323-32195-2.
85. Meningeal Neoplasms—Advances in Research and Treatment: 2012 Edition: ScholarlyBrief. ScholarlyEditions. 26 December 2012. pp. 99–. ISBN   978-1-4816-0002-6.
86. Dickman A (27 September 2012). Drugs in Palliative Care. OUP Oxford. pp. 137–138. ISBN   978-0-19-966039-1.
87. Schmutz JL (May 2018). "Méningiomes et acétate de cyprotérone: mise au point" [Cyproterone acetate and meningioma: The latest findings]. Ann Dermatol Venereol (in French). 145 (5): 390–391. doi:10.1016/j.annder.2018.04.001. PMID   29703641.
88. Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MW, Thijssen JH (2000). "Occurrence, regulation, and significance of progesterone receptors in human meningioma". Steroids. 65 (10–11): 795–800. doi:10.1016/S0039-128X(00)00193-8. PMID   11108890. S2CID   21030157.
89. Shlomo Melmed (9 December 2010). The Pituitary. Academic Press. pp. 227–. ISBN   978-0-12-380927-8.
90. Knobil and Neill's Physiology of Reproduction. Academic Press. 12 December 2005. pp. 1557–. ISBN   978-0-08-053527-2.
91. Marc A. Fritz; Leon Speroff (2011). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 1091–. ISBN   978-0-7817-7968-5.
92. Mancini I, Rotilio A, Coati I, Seracchioli R, Martelli V, Meriggiola MC (June 2018). "Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review". Gynecol. Endocrinol. 34 (6): 456–459. doi:10.1080/09513590.2017.1395839. PMID   29105524. S2CID   20655235.
93. Ter Wengel PV, Martin E, Gooren L, Den Heijer M, Peerdeman SM (December 2016). "Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature". Andrologia. 48 (10): 1130–1137. doi: 10.1111/and.12550 . PMID   26888610. S2CID   10465392.
94. Gruber CJ, Huber JC (December 2003). "Differential effects of progestins on the brain". Maturitas. 46 (Suppl 1): S71–5. doi:10.1016/j.maturitas.2003.09.021. PMID   14670648.
95. Hensiek AE, Kellerman AJ, Hill JT (August 2000). "Spontaneous regression of a solitary cerebral metastases in renal carcinoma followed by meningioma development under medroxyprogesterone acetate therapy". Br J Neurosurg. 14 (4): 354–6. doi:10.1080/026886900417388. PMID   11045205. S2CID   219188080.
96. Passeri T, Champagne PO, Bernat AL, Hanakita S, Salle H, Mandonnet E, Froelich S (April 2019). "Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients". Acta Neurochir (Wien). 161 (4): 761–765. doi:10.1007/s00701-019-03848-x. PMID   30783806. S2CID   67750259.
97. Gooren LJ, Assies J, Asscheman H, de Slegte R, van Kessel H (February 1988). "Estrogen-induced prolactinoma in a man". J. Clin. Endocrinol. Metab. 66 (2): 444–6. doi:10.1210/jcem-66-2-444. PMID   3339116.
98. Serri O, Noiseux D, Robert F, Hardy J (September 1996). "Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient". J. Clin. Endocrinol. Metab. 81 (9): 3177–9. doi: 10.1210/jcem.81.9.8784065 . PMID   8784065.
99. García-Malpartida K, Martín-Gorgojo A, Rocha M, Gómez-Balaguer M, Hernández-Mijares A (August 2010). "Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual". Fertil. Steril. 94 (3): 1097.e13–5. doi: 10.1016/j.fertnstert.2010.01.076 . PMID   20227072.
100. Bunck MC, Debono M, Giltay EJ, Verheijen AT, Diamant M, Gooren LJ (2009). "Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages". BMJ Case Rep. 2009: bcr0220091589. doi:10.1136/bcr.02.2009.1589. PMC   3029513 . PMID   21829422.
101. Cunha FS, Domenice S, Câmara VL, Sircili MH, Gooren LJ, Mendonça BB, Costa EM (August 2015). "Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy". Andrologia. 47 (6): 680–4. doi: 10.1111/and.12317 . PMID   25059808. S2CID   37467592.
102. Gazzeri R, Galarza M, Gazzeri G (December 2007). "Growth of a meningioma in a transsexual patient after estrogen-progestin therapy". N. Engl. J. Med. 357 (23): 2411–2. doi: 10.1056/NEJMc071938 . PMID   18057351.
103. Deipolyi AR, Han SJ, Parsa AT (October 2010). "Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy". J Clin Neurosci. 17 (10): 1324–6. doi:10.1016/j.jocn.2010.01.036. PMID   20594855. S2CID   206313070.
104. Cebula H, Pham TQ, Boyer P, Froelich S (November 2010). "Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient". Acta Neurochir (Wien). 152 (11): 1955–6. doi:10.1007/s00701-010-0787-2. PMID   20811919. S2CID   947448.
105. Bergoglio MT, Gómez-Balaguer M, Almonacid Folch E, Hurtado Murillo F, Hernández-Mijares A (May 2013). "Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual". Endocrinol Nutr. 60 (5): 264–7. doi:10.1016/j.endonu.2012.07.004. PMID   23022362.
106. Mueller A, Gooren L (September 2008). "Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones". Eur. J. Endocrinol. 159 (3): 197–202. doi:10.1530/EJE-08-0289. PMID   18567667.
107. Cea-Soriano L, Blenk T, Wallander MA, Rodríguez LA (April 2012). "Hormonal therapies and meningioma: is there a link?". Cancer Epidemiol. 36 (2): 198–205. doi:10.1016/j.canep.2011.08.003. PMID   21943794.
108. Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (November 2017). "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline". J. Clin. Endocrinol. Metab. 102 (11): 3869–3903. doi: 10.1210/jc.2017-01658 . PMID   28945902.
109. McFarlane T, Zajac JD, Cheung AS (December 2018). "Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review". Clin. Endocrinol. (Oxf). 89 (6): 700–711. doi: 10.1111/cen.13835 . hdl: 11343/284360 . PMID   30107028.
110. Oettel M, Schillinger E (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 544–. ISBN   978-3-642-60107-1.
111. Kovacs K, Stefaneanu L, Ezzat S, Smyth HS (May 1994). "Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study". Arch. Pathol. Lab. Med. 118 (5): 562–5. PMID   8192565.
112. Giraldi, Laura; Hansen, Jørgen Vinsløv; Wohlfahrt, Jan; Melbye, Mads; Fugleholm, Kåre; Munch, Tina Nørgaard (2019). "Male hormone-interfering drugs and meningioma development". Neuro-Oncology Advances. 1: vdz046. doi: 10.1093/noajnl/vdz046 . ISSN   2632-2498. PMC   7212874 . PMID   32642670.
113. Kang BM, Youn SM (October 2019). "A Case of Sporadic Suprasellar Hemangioblastoma Mimicking Meningioma". Brain Tumor Res Treat. 7 (2): 147–150. doi:10.14791/btrt.2019.7.e40. PMC   6829077 . PMID   31686447.
114. Gooren LJ, Assies J, Asscheman H, de Slegte R, van Kessel H (February 1988). "Estrogen-induced prolactinoma in a man". J. Clin. Endocrinol. Metab. 66 (2): 444–6. doi:10.1210/jcem-66-2-444. PMID   3339116.
115. Serri O, Noiseux D, Robert F, Hardy J (September 1996). "Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient". J. Clin. Endocrinol. Metab. 81 (9): 3177–9. doi:10.1210/jcem.81.9.8784065. PMID   8784065.
116. Bunck MC, Debono M, Giltay EJ, Verheijen AT, Diamant M, Gooren LJ (2009). "Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages". BMJ Case Rep. 2009: bcr0220091589. doi:10.1136/bcr.02.2009.1589. PMC   3029513 . PMID   21829422.
117. García-Malpartida K, Martín-Gorgojo A, Rocha M, Gómez-Balaguer M, Hernández-Mijares A (August 2010). "Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual". Fertil. Steril. 94 (3): 1097.e13–5. doi:10.1016/j.fertnstert.2010.01.076. PMID   20227072.
118. Cunha FS, Domenice S, Câmara VL, Sircili MH, Gooren LJ, Mendonça BB, Costa EM (August 2015). "Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy". Andrologia. 47 (6): 680–4. doi:10.1111/and.12317. PMID   25059808.
119. Nota NM, Wiepjes CM, de Blok C, Gooren LJ, Peerdeman SM, Kreukels B, den Heijer M (July 2018). "The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment". Brain. 141 (7): 2047–2054. doi:10.1093/brain/awy108. PMID   29688280.
120. Asscheman H, Gooren LJ, Assies J, Smits JP, de Slegte R (June 1988). "Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals". Clin. Endocrinol. (Oxf). 28 (6): 583–8. doi:10.1111/j.1365-2265.1988.tb03849.x. PMID   2978262.
121. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ (September 1997). "Mortality and morbidity in transsexual subjects treated with cross-sex hormones". Clin. Endocrinol. (Oxf). 47 (3): 337–42. doi:10.1046/j.1365-2265.1997.2601068.x. PMID   9373456.
122. Kovacs K, Stefaneanu L, Ezzat S, Smyth HS (May 1994). "Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study". Arch. Pathol. Lab. Med. 118 (5): 562–5. PMID   8192565.
123. Futterweit W (April 1998). "Endocrine therapy of transsexualism and potential complications of long-term treatment". Arch Sex Behav. 27 (2): 209–26. doi:10.1023/A:1018638715498. PMID   9562902.
124. McFarlane T, Zajac JD, Cheung AS (December 2018). "Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review". Clin. Endocrinol. (Oxf). 89 (6): 700–711. doi:10.1111/cen.13835. PMID   30107028.
125. Gazzeri R, Galarza M, Gazzeri G (December 2007). "Growth of a meningioma in a transsexual patient after estrogen-progestin therapy". N. Engl. J. Med. 357 (23): 2411–2. doi:10.1056/NEJMc071938. PMID   18057351.
126. Cebula H, Pham TQ, Boyer P, Froelich S (November 2010). "Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient". Acta Neurochir (Wien). 152 (11): 1955–6. doi:10.1007/s00701-010-0787-2. PMID   20811919. S2CID   947448.
127. Gonçalves AM, Page P, Domigo V, Méder JF, Oppenheim C (September 2010). "Abrupt regression of a meningioma after discontinuation of cyproterone treatment". AJNR Am J Neuroradiol. 31 (8): 1504–5. doi:10.3174/ajnr.A1978. PMID   20053802. S2CID   14800959.
128. Gil M, Oliva B, Timoner J, Maciá MA, Bryant V, de Abajo FJ (December 2011). "Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study". Br J Clin Pharmacol. 72 (6): 965–8. doi:10.1111/j.1365-2125.2011.04031.x. PMC   3244644 . PMID   21627676.
129. Bergoglio MT, Gómez-Balaguer M, Almonacid Folch E, Hurtado Murillo F, Hernández-Mijares A (May 2013). "Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual". Endocrinol Nutr. 60 (5): 264–7. doi:10.1016/j.endonu.2012.07.004. PMID   23022362.
130. Knight, Ema J.; McDonald, Matthew J. (2013). "Recurrence and Progression of Meningioma in Male-to-Female Transgender Individuals During Exogenous Hormone Use". International Journal of Transgenderism. 14 (1): 18–23. doi:10.1080/15532739.2012.725563. ISSN   1553-2739. S2CID   56492694.
131. Razavi, Hamid Borghei (2014). "Meningioma: The Unusual Growth in a Transsexual Patient after Estrogen-Progesterone Therapy". SOJ Neurology. 1 (2). doi:10.15226/2374-6858/1/2/00109. ISSN   2374-6858.
132. Bernat AL, Oyama K, Hamdi S, Mandonnet E, Vexiau D, Pocard M, George B, Froelich S (October 2015). "Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients". Acta Neurochir (Wien). 157 (10): 1741–6. doi:10.1007/s00701-015-2532-3. PMID   26264069. S2CID   27512648.
133. Botella C, Coll G, Lemaire JJ, Irthum B (October 2015). "Méningiomes intracrâniens et utilisation prolongée d'acétate de cyprotérone à dose conventionnelle chez la femme : à propos de deux cas de régression tumorale après arrêt du traitement" [Intra cranial meningiomas and long term use of cyproterone acetate with a conventional dose in women. A report of two cases of tumor decrease after treatment withdrawal]. Neurochirurgie (in French). 61 (5): 339–42. doi:10.1016/j.neuchi.2015.05.002. PMID   26249273.
134. Sys C, Kestelyn P (2015). "Unilateral proptosis and blindness caused by meningioma in a patient treated with cyproterone acetate". GMS Ophthalmol Cases. 5: Doc05. doi:10.3205/oc000027. PMC   5015623 . PMID   27625949.
135. Ter Wengel PV, Martin E, Gooren L, Den Heijer M, Peerdeman SM (December 2016). "Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature". Andrologia. 48 (10): 1130–1137. doi:10.1111/and.12550. PMID   26888610. S2CID   10465392.
136. Nota NM, Wiepjes CM, de Blok C, Gooren LJ, Peerdeman SM, Kreukels B, den Heijer M (July 2018). "The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment". Brain. 141 (7): 2047–2054. doi:10.1093/brain/awy108. PMID   29688280.
137. Kalamarides M, Peyre M (May 2017). "Dramatic Shrinkage with Reduced Vascularization of Large Meningiomas After Cessation of Progestin Treatment". World Neurosurg. 101: 814.e7–814.e10. doi:10.1016/j.wneu.2017.03.013. PMID   28300711.
138. Keilani C, Abada S (May 2017). "An uncommon case of symptomatic multiple meningiomas with bilateral compressive optic neuropathy rapidly induced under cyproterone acetate treatment". Curr Drug Saf. 12 (2). doi:10.2174/1574886312666170523154548. PMID   28545357.
139. Bernat AL, Bonnin S, Labidi M, Aldahak N, Bresson D, Bouazza S, Froelich S (2018). "Regression of Giant Olfactory Groove Meningioma and Complete Visual Acuity Recovery after Discontinuation of Cyproterone Acetate". J Ophthalmic Vis Res. 13 (3): 355–358. doi: 10.4103/jovr.jovr_21_17 . PMC   6058554 . PMID   30090195.
140. Boer, Mirra; Moernaut, Loes; Van Calenbergh, Frank; Lapauw, Bruno; T'Sjoen, Guy (2018). "Variation of meningioma in response to cyproterone acetate in a trans woman". International Journal of Transgenderism. 19 (1): 92–94. doi:10.1080/15532739.2017.1413615. ISSN   1553-2739. S2CID   148986470.
141. Mancini I, Rotilio A, Coati I, Seracchioli R, Martelli V, Meriggiola MC (June 2018). "Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review". Gynecol. Endocrinol. 34 (6): 456–459. doi:10.1080/09513590.2017.1395839. PMID   29105524. S2CID   20655235.
142. Nizar, Hisham; Seal, Leighton (2018). "Unusual cause of meningioma". Endocrine Abstracts. doi:10.1530/endoabs.59.EP75. ISSN   1479-6848. S2CID   59204730.
143. Raj R, Korja M, Koroknay-Pál P, Niemelä M (2018). "Multiple meningiomas in two male-to-female transsexual patients with hormone replacement therapy: A report of two cases and a brief literature review". Surg Neurol Int. 9: 109. doi: 10.4103/sni.sni_22_18 . PMC   5991277 . PMID   29930875.
144. Chasseur, P; Bruneau, M; Corvilain, B (2019). "A case of meningioma after cyproterone acetate use". Endocrine Abstracts. doi:10.1530/endoabs.64.024. ISSN   1479-6848. S2CID   208487289.
145. Alalade, Andrew; Millward, Christopher; Pal, Piyali; Gilkes, Catherine (2019). "Multiple Skull Base Meningiomata in a Transgender Patient: Case Report and Literature Review". Journal of Neurological Surgery Part B: Skull Base. 80: S1–S244. doi:10.1055/s-0039-1679816. ISSN   2193-634X. S2CID   88082457. 29th Annual Meeting North American Skull Base Society.
146. Champagne PO, Passeri T, Froelich S (March 2019). "Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report". Acta Neurochir (Wien). 161 (3): 589–592. doi:10.1007/s00701-018-03782-4. PMID   30666456. S2CID   58573065.
147. Owens, Lisa; Halliday, Jane; Kerr, Richard; Franks, Stephen (2019). "A case of meningioma associated with long-term use of cyproterone acetate". Endocrine Abstracts. doi:10.1530/endoabs.62.P36. ISSN   1479-6848. S2CID   145949327.
148. Colstrup, Hans; Larsen, Ellen D.; Mollerup, Steen; Tarp, Hanne; Soelberg, Jacob; Rosthøj, Susanne (2020). "Long-term follow-up of 60 incarcerated male sexual offenders pharmacologically castrated with a combination of GnRH agonist and cyproterone acetate". The Journal of Forensic Psychiatry & Psychology. 31 (2): 1–14. doi:10.1080/14789949.2020.1711957. ISSN   1478-9949. S2CID   213099389.
149. Froelich S, Dali-Youcef N, Boyer P, Kehrli P, Maitrot D, Auwerx J, Schlienger JL (2008). "Does cyproterone acetate promote multiple meningiomas?". Endocrine Abstracts. 16: P158. ISSN   1470-3947.
150. Cea-Soriano L, Blenk T, Wallander MA, Rodríguez LA (April 2012). "Hormonal therapies and meningioma: is there a link?". Cancer Epidemiol. 36 (2): 198–205. doi:10.1016/j.canep.2011.08.003. PMID   21943794.
151. Peyre M, Gaillard S, de Marcellus C, Giry M, Bielle F, Villa C, Boch AL, Loiseau H, Baussart B, Cazabat L, Raffin-Sanson ML, Sanson M, Kalamarides M (March 2018). "Progestin-associated shift of meningioma mutational landscape". Ann. Oncol. 29 (3): 681–686. doi:10.1093/annonc/mdx763. PMID   29206892.
152. Portet, Sylvain; Naoufal, Rania; Tachon, Gaëlle; Simonneau, Adrien; Chalant, Anaïs; Naar, Amir; Milin, Serge; Bataille, Benoit; Karayan-Tapon, Lucie (2019). "Histo-Molecular Characterization of Intracranial Meningiomas Developed in Patients Exposed to High-Dose Cyproterone Acetate, An Antiandrogen Treatment". Neuro-Oncology Advances. doi:10.1093/noajnl/vdz003. ISSN   2632-2498. PMID   32642646.
153. Deipolyi AR, Han SJ, Parsa AT (October 2010). "Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy". J Clin Neurosci. 17 (10): 1324–6. doi:10.1016/j.jocn.2010.01.036. PMID   20594855. S2CID   206313070.
154. McFarlane T, Zajac JD, Cheung AS (December 2018). "Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review". Clin. Endocrinol. (Oxf). 89 (6): 700–711. doi:10.1111/cen.13835. PMID   30107028. S2CID   52003943.
155. Vasilakis-Scaramozza C, Jick H (October 2001). "Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives". Lancet. 358 (9291): 1427–9. doi:10.1016/S0140-6736(01)06522-9. PMID   11705493. S2CID   45593566.
156. Spitzer WO (December 2003). "Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation". J Obstet Gynaecol Can. 25 (12): 1011–8. doi:10.1016/S1701-2163(16)30342-5. PMID   14663535.
157. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E (October 2011). "Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9". BMJ. 343: d6423. doi:10.1136/bmj.d6423. PMC   3202015 . PMID   22027398.
158. Kromm J, Jeerakathil T (June 2014). "Cyproterone acetate-ethinyl estradiol use in a 23-year-old woman with stroke". CMAJ. 186 (9): 690–3. doi:10.1503/cmaj.130579. PMC   4049993 . PMID   24491473.
159. Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID   16112947. S2CID   24616324.
160. Wiegratz I, Kuhl H (September 2006). "Metabolic and clinical effects of progestogens". Eur J Contracept Reprod Health Care. 11 (3): 153–61. doi:10.1080/13625180600772741. PMID   17056444. S2CID   27088428.
161. Asscheman H, T'Sjoen G, Lemaire A, Mas M, Meriggiola MC, Mueller A, Kuhn A, Dhejne C, Morel-Journel N, Gooren LJ (September 2014). "Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review". Andrologia. 46 (7): 791–5. doi: 10.1111/and.12150 . hdl:11585/413984. PMID   23944849. S2CID   5363824.
162. Beyer-Westendorf J, Werth S, Halbritter K, Weiss N (April 2010). "Cancer in males and risk of venous thromboembolism". Thromb. Res. 125 (Suppl 2): S155–9. doi:10.1016/S0049-3848(10)70035-9. PMID   20433997.
163. Guay DR (December 2008). "Inappropriate sexual behaviors in cognitively impaired older individuals". Am J Geriatr Pharmacother. 6 (5): 269–88. doi:10.1016/j.amjopharm.2008.12.004. PMID   19161930.
164. Seaman HE, Langley SE, Farmer RD, de Vries CS (June 2007). "Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database". BJU Int. 99 (6): 1398–403. doi:10.1111/j.1464-410X.2007.06859.x. PMID   17537215.
165. Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, Lambe M, Stattin P, Holmberg L (May 2010). "Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden". Lancet Oncol. 11 (5): 450–8. doi:10.1016/S1470-2045(10)70038-3. PMC   2861771 . PMID   20395174.
166. Namer M (October 1988). "Clinical applications of antiandrogens". J. Steroid Biochem. 31 (4B): 719–29. doi:10.1016/0022-4731(88)90023-4. PMID   2462132.
167. Jacobi, GR; Tunn, UW; Senge, TH (1 December 1982). "Clinical experience with cyproterone acetate for palliation of inoperable prostate cancer". In Jacobi, Günther H; Hohenfellner, Rudolf (eds.). Prostate Cancer. Williams & Wilkins. pp. 305–319. ISBN   978-0-683-04354-9.
168. Schröder, Fritz H.; Radlmaier, Albert (2009). "Steroidal Antiandrogens". In V. Craig Jordan; Barrington J. A. Furr (eds.). Hormone Therapy in Breast and Prostate Cancer. Humana Press. pp. 325–346. doi:10.1007/978-1-59259-152-7_15. ISBN   978-1-60761-471-5.
169. de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S (February 1986). "Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762". J Urol. 135 (2): 303–7. doi:10.1016/s0022-5347(17)45620-5. PMID   2935644.
170. Schröder FH (1998). "Antiandrogens as monotherapy for prostate cancer". European Urology. 34 (Suppl 3): 12–7. doi:10.1159/000052291. PMID   9854190. S2CID   24831338.
171. Beyer-Westendorf J, Bauersachs R, Hach-Wunderle V, Zotz RB, Rott H (October 2018). "Sex hormones and venous thromboembolism - from contraception to hormone replacement therapy". VASA. Zeitschrift für Gefässkrankheiten. 47 (6): 441–450. doi:10.1024/0301-1526/a000726. PMID   30008249. S2CID   51628832.
172. DeLoughery TG (June 2011). "Estrogen and thrombosis: controversies and common sense". Rev Endocr Metab Disord. 12 (2): 77–84. doi:10.1007/s11154-011-9178-0. PMID   21559819. S2CID   28053690.
173. Van Hylckama Vlieg, A.; Middeldorp, S. (2011). "Hormone therapies and venous thromboembolism: where are we now?". Journal of Thrombosis and Haemostasis. 9 (2): 257–266. doi: 10.1111/j.1538-7836.2010.04148.x . ISSN   1538-7933. PMID   21114755. S2CID   32394836.
174. Benagiano, G.; Primiero, F.M. (1983). "Long Acting Contraceptives Present Status". Drugs. 25 (6): 570–609. doi:10.2165/00003495-198325060-00003. ISSN   0012-6667. PMID   6223801. S2CID   45898359.
175. Mantha, S.; Karp, R.; Raghavan, V.; Terrin, N.; Bauer, K. A.; Zwicker, J. I. (2012). "Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis". BMJ. 345 (aug07 2): e4944. doi:10.1136/bmj.e4944. ISSN   1756-1833. PMC   3413580 . PMID   22872710.
176. Singh, Shankar; Gauthier, Sylvain; Labrie, Fernand (2000). "Androgen Receptor Antagonists (Antiandrogens) Structure-Activity Relationships". Current Medicinal Chemistry. 7 (2): 211–247. doi:10.2174/0929867003375371. ISSN   0929-8673. PMID   10637363. When compared to flutamide, [cyproterone acetate] has significant intrinsic androgenic and estrogenic activities. [...] The effects of flutamide and the steroidal derivatives, cyproterone acetate, chlormadinone acetate, megestrol acetate and medroxyprogesterone acetate were compared in vivo in female nude mice bearing androgen-sensitive Shionogi tumors. All steroidal compounds stimulated tumor growth while flutamide had no stimulatory effect [51]. Thus, CPA due to its intrinsic properties stimulates androgen-sensitive parameters and cancer growth. Cyproterone acetate added to castration has never been shown in any controlled study to prolong disease-free survival or overall survival in prostate cancer when compared with castration alone [152-155].
177. Newling DW (March 1997). "The palliative therapy of advanced prostate cancer, with particular reference to the results of recent European clinical trials". Br J Urol. 79 (Suppl 1): 72–81. doi:10.1111/j.1464-410X.1997.tb00805.x. PMID   9088277.
178. Mahler C, Verhelst J, Denis L (May 1998). "Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer". Clin Pharmacokinet. 34 (5): 405–17. doi:10.2165/00003088-199834050-00005. PMID   9592622. S2CID   25200595.
179. Anderson J (March 2003). "The role of antiandrogen monotherapy in the treatment of prostate cancer". BJU Int. 91 (5): 455–61. doi:10.1046/j.1464-410X.2003.04026.x. PMID   12603397.
180. Aronson JK (21 February 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. pp. 150–152. ISBN   978-0-08-093292-7.
181. Müller E (18 September 2003). Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance: From Basic to Clinical Research. Springer Science & Business Media. pp. 171–. ISBN   978-88-470-0295-1. Archived from the original on 8 September 2017. [CPA] induces relevant effects on the coagulative system. A recent meta-analysis relating to total androgenic blockade has shown that cyproterone acetate when combined with castration reduces the long-term efficacy of androgen-suppressive treatments. In fact, it causes an increase in treatment-related mortality, mainly due to cardiovascular complications (No authors, 2000).
182. Furr BJ, Tucker H (January 1996). "The preclinical development of bicalutamide: pharmacodynamics and mechanism of action". Urology. 47 (1A Suppl): 13–25, discussion 29–32. doi:10.1016/S0090-4295(96)80003-3. PMID   8560673.
183. Mahler C, Verhelst J, Denis L (May 1998). "Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer". Clinical Pharmacokinetics. 34 (5): 405–17. doi:10.2165/00003088-199834050-00005. PMID   9592622. S2CID   25200595.
184. Chang C (22 March 2005). Prostate Cancer: Basic Mechanisms and Therapeutic Approaches. World Scientific. pp. 10–11. ISBN   978-981-4481-61-8. Archived from the original on 8 September 2017.
185. Gillatt D (August 2006). "Antiandrogen treatments in locally advanced prostate cancer: are they all the same?". J. Cancer Res. Clin. Oncol. 132 (Suppl 1): S17–26. doi:10.1007/s00432-006-0133-5. PMID   16845534. S2CID   23888640.
186. Davey DA (March 2018). "Menopausal hormone therapy: a better and safer future". Climacteric. 21 (5): 454–461. doi:10.1080/13697137.2018.1439915. PMID   29526116. S2CID   3850275.
187. Stanczyk FZ, Bhavnani BR (July 2014). "Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe?". J. Steroid Biochem. Mol. Biol. 142: 30–8. doi:10.1016/j.jsbmb.2013.11.011. PMID   24291402. S2CID   22731802.
188. Sturdee DW (August 2013). "Are progestins really necessary as part of a combined HRT regimen?". Climacteric. 16 (Suppl 1): 79–84. doi:10.3109/13697137.2013.803311. PMID   23651281. S2CID   21894200.
189. de Blok CJ, Wiepjes CM, Nota NM, van Engelen K, Adank MA, Dreijerink KM, Barbé E, Konings IR, den Heijer M (May 2019). "Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands". BMJ. 365: l1652. doi:10.1136/bmj.l1652. PMC   6515308 . PMID   31088823.
190. de Blok CJ, Dreijerink KM, den Heijer M (June 2019). "Cancer Risk in Transgender People". Endocrinol. Metab. Clin. North Am. 48 (2): 441–452. doi:10.1016/j.ecl.2019.02.005. PMID   31027551. S2CID   135382400.
191. Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, Nota NM, den Heijer M, Gooren LJ (2000). Evaluation and Treatment of Gender-Dysphoric/Gender Incongruent Adults. MDText.com. PMID   31343858.
192. Iwamoto SJ, Defreyne J, Rothman MS, Van Schuylenbergh J, Van de Bruaene L, Motmans J, T'Sjoen G (2019). "Health considerations for transgender women and remaining unknowns: a narrative review". Ther Adv Endocrinol Metab. 10: 2042018819871166. doi:10.1177/2042018819871166. PMC   6719479 . PMID   31516689.
193. Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B (December 2011). "Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide". Contraception. 84 (6): 549–57. doi:10.1016/j.contraception.2011.04.009. PMID   22078182.
194. Neumann F, Kalmus J (1991). "Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience". Exp. Clin. Endocrinol. 98 (2): 71–80. doi:10.1055/s-0029-1211103. PMID   1838080.
195. Ahmadi H, Daneshmand S (2014). "Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes". Patient Relat Outcome Meas. 5: 63–70. doi: 10.2147/PROM.S52788 . PMC   4094624 . PMID   25045284.
196. Russell N, Cheung A, Grossmann M (August 2017). "Estradiol for the mitigation of adverse effects of androgen deprivation therapy". Endocr. Relat. Cancer. 24 (8): R297–R313. doi: 10.1530/ERC-17-0153 . PMID   28667081.
197. Dalesio O, van Tinteren H, Clarke M, Peto R, Schroder F, Dechering I, Evans V, Godwin J, Blumenstein B, Crawford E, Denis L, Hall R, Hill C, Iversen P, Shipley W, Soloway M, Sylvester R (2000). "Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials". The Lancet. 355 (9214): 1491–1498. doi:10.1016/S0140-6736(00)02163-2. ISSN   0140-6736. S2CID   25366526.
198. Chodak G, Gomella L, Phung de H (September 2007). "Combined androgen blockade in advanced prostate cancer: looking back to move forward". Clin Genitourin Cancer. 5 (6): 371–8. doi:10.3816/CGC.2007.n.019. PMID   17956709.
199. Coleman, E.; et al. (19 August 2022). "Standards of Care for the Health of Transgender and Gender Diverse People, Version 8". International Journal of Transgender Health . 23 (Suppl 1): S1–S259. doi: 10.1080/26895269.2022.2100644 . ISSN   2689-5269. PMC   9553112 . PMID   36238954.
200. Godsland IF, Wynn V, Crook D, Miller NE (December 1987). "Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions". American Heart Journal. 114 (6): 1467–1503. doi:10.1016/0002-8703(87)90552-7. PMID   3318361.
201. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J (June 2019). "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Circulation. 139 (25): e1082–e1143. doi:10.1161/CIR.0000000000000625. PMC   7403606 . PMID   30586774.
202. Lax ER (1987). "Mechanisms of physiological and pharmacological sex hormone action on the mammalian liver". Journal of Steroid Biochemistry. 27 (4–6): 1119–1128. doi:10.1016/0022-4731(87)90198-1. PMID   3320549.
203. Lax ER, Baumann P, Schriefers H (August 1983). "Antiandrogenic effects of oestradiol on enzyme activities of hepatic steroid metabolism". Experimental and Clinical Endocrinology. 82 (2): 145–152. doi:10.1055/s-0029-1210270. PMID   6578932.
204. Baldani DP, Skrgatic L, Ougouag R, Kasum M (February 2018). "The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment". Gynecol Endocrinol. 34 (2): 87–91. doi:10.1080/09513590.2017.1381681. PMID   28944709. S2CID   205631980.
205. Nakhjavani M, Hamidi S, Esteghamati A, Abbasi M, Nosratian-Jahromi S, Pasalar P (October 2009). "Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism". Br J Clin Pharmacol. 68 (4): 634–7. doi:10.1111/j.1365-2125.2009.03483.x. PMC   2780289 . PMID   19843067.
206. Cignarella A, Mioni R, Sabbadin C, Dassie F, Parolin M, Vettor R, Barbot M, Scaroni C (December 2020). "Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS". Int J Mol Sci. 21 (24): 9554. doi: 10.3390/ijms21249554 . PMC   7765466 . PMID   33334002.
207. Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, Motta C, De Leo V, Petraglia F, Lenzi A (March 2018). "Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial". J. Clin. Endocrinol. Metab. 103 (3): 824–838. doi: 10.1210/jc.2017-01186 . PMID   29211888.
208. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR (April 2013). "Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects". Endocr. Rev. 34 (2): 171–208. doi:10.1210/er.2012-1008. PMC   3610676 . PMID   23238854.
209. Jiang Y, Tian W (November 2017). "The effects of progesterones on blood lipids in hormone replacement therapy". Lipids Health Dis. 16 (1): 219. doi: 10.1186/s12944-017-0612-5 . PMC   5697110 . PMID   29157280.
210. DeLeve, Laurie D. (2013). "Cancer Chemotherapy". Drug-Induced Liver Disease. pp. 541–567. doi:10.1016/B978-0-12-387817-5.00030-3. ISBN   9780123878175.
211. Kim JH, Yoo BW, Yang WJ (May 2014). "Hepatic failure induced by cyproterone acetate: A case report and literature review". Can Urol Assoc J. 8 (5–6): E458–61. doi:10.5489/cuaj.1753. PMC   4081269 . PMID   25024808.
212. Savidou I, Deutsch M, Soultati AS, Koudouras D, Kafiri G, Dourakis SP (December 2006). "Hepatotoxicity induced by cyproterone acetate: a report of three cases". World Journal of Gastroenterology. 12 (46): 7551–5. doi: 10.3748/wjg.v12.i46.7551 . PMC   4087608 . PMID   17167851.
213. Hinkel A, Berges RR, Pannek J, Schulze H, Senge T (1996). "Cyproterone acetate in the treatment of advanced prostatic cancer: retrospective analysis of liver toxicity in the long-term follow-up of 89 patients". Eur. Urol. 30 (4): 464–70. doi:10.1159/000474216. PMID   8977068.
214. Rabe T, Feldmann K, Heinemann L, Runnebaum B (January 1996). "Cyproterone acetate: is it hepato- or genotoxic?". Drug Saf. 14 (1): 25–38. doi:10.2165/00002018-199614010-00004. PMID   8713486. S2CID   11589326. Recently, a publication of the Medicines Control Agency (MCA)/Committee on Safety of Medicines (CSM)[5] drew attention to spontaneous reports of serious and dose-related hepatic toxicity after the prolonged use of CPA. [...] 96 hepatotoxic events (33 fatal) have been observed, of which 91 were in males and 5 in females. The hepatic reactions included hepatitis, cholestatic jaundice and hepatic failure. The majority of patients were treated with high dosages of CPA (300 mg/day) for cancer of the prostate.
215. "Hepatic reactions with cyproterone acetate (Cyprostat, Androcur)". Current Problems in Pharmacovigilance (21): 1. February 1995.
216. Gava, Giulia; Seracchioli, Renato; Meriggiola, Maria Cristina (2017). "Therapy with Antiandrogens in Gender Dysphoric Natal Males". Endocrinology of the Testis and Male Reproduction. pp. 1199–1209. doi:10.1007/978-3-319-44441-3_42. ISBN   978-3-319-44440-6. ISSN   2510-1927.
217. Bessone F, Lucena MI, Roma MG, Stephens C, Medina-Cáliz I, Frider B, Tsariktsian G, Hernández N, Bruguera M, Gualano G, Fassio E, Montero J, Reggiardo MV, Ferretti S, Colombato L, Tanno F, Ferrer J, Zeno L, Tanno H, Andrade RJ (February 2016). "Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases". Liver Int. 36 (2): 302–10. doi:10.1111/liv.12899. PMID   26104271. S2CID   33393791.
218. Marius Duker (23 May 2016). Incapacitation: Trends and New Perspectives. Routledge. pp. 139–. ISBN   978-1-317-11767-4.
219. Berlex Canada, Inc. (2003-02-10). "Cyproterone Acetate Tablets and Injections Product Monographs (revised version)" (PDF). Archived from the original (PDF) on 2006-09-24.
220. Adverse Drug Reactions Advisory Committee (February 2004). "Australian Adverse Drug Reactions Bulletin, Volume 23, Number 1".
221. Kumar P, Reddy S, Kulkarni A, Sharma M, Rao PN (2021). "Cyproterone Acetate-Induced Acute Liver Failure: A Case Report and Review of the Literature". J Clin Exp Hepatol. 11 (6): 739–741. doi:10.1016/j.jceh.2021.01.003. PMC   8617532 . PMID   34866850.
222. Lin AD, Chen KK, Lin AT, Chang YH, Wu HH, Kuo JY, Huang WJ, Hsu YS, Chung HJ, Chang LS (December 2003). "Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer". J Chin Med Assoc. 66 (12): 735–40. PMID   15015823.
223. Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A (2004). "Hepatotoxicity induced by antiandrogens: a review of the literature". Urol. Int. 73 (4): 289–95. doi:10.1159/000081585. PMID   15604569. S2CID   24799765.
224. Chitturi, Shivakumar; Farrell, Geoffrey C (2013). "Adverse Effects of Hormones and Hormone Antagonists on the Liver". Drug-Induced Liver Disease. pp. 605–619. doi:10.1016/B978-0-12-387817-5.00033-9. ISBN   9780123878175.
225. Miquel M, Soler A, Vaqué A, Ojanguren I, Costa J, Planas R (October 2007). "Suspected cross-hepatotoxicity of flutamide and cyproterone acetate". Liver Int. 27 (8): 1144–7. doi:10.1111/j.1478-3231.2007.01549.x. PMID   17845544. S2CID   23120975.
226. Manolakopoulos S, Bethanis S, Armonis A, Economou M, Avgerinos A, Tzourmakliotis D (March 2004). "Toxic hepatitis after sequential administration of flutamide and cyproterone acetate". Dig. Dis. Sci. 49 (3): 462–5. doi:10.1023/B:DDAS.0000020504.41500.9c. PMID   15139499. S2CID   42497536.
227. Fisher, Alessandra D.; Bandini, Elisa; Casale, Helen; Maggi, Mario (29 November 2011), "Paraphilic Disorders: Diagnosis and Treatment", Hormonal Therapy for Male Sexual Dysfunction, Wiley, pp. 94–110, doi:10.1002/9781119963820.ch8, hdl: 2158/426102 , ISBN   9780470657607
228. Meijers WH, Willemse PH, Sleijfer DT, Mulder NH, Grond J (September 1986). "Hepatocellular damage by cyproterone acetate". Eur J Cancer Clin Oncol. 22 (9): 1121–2. doi:10.1016/0277-5379(86)90017-9. PMID   2946585.
229. Lévesque H, Trivalle C, Manchon ND, Vinel JP, Moore N, Hémet J, Courtois H, Bercoff E, Bourreille J (January 1989). "Fulminant hepatitis due to cyproterone acetate". Lancet. 1 (8631): 215–6. doi:10.1016/S0140-6736(89)91225-7. PMID   2563116. S2CID   45452406.
230. Blake JC, Sawyerr AM, Dooley JS, Scheuer PJ, McIntyre N (May 1990). "Severe hepatitis caused by cyproterone acetate". Gut. 31 (5): 556–7. doi:10.1136/gut.31.5.556. PMC   1378574 . PMID   2140997. Although few case reports have been published, the Committee on Safety of Medicines had received 19 reports in the UK of adverse hepatic reactions associated with cyproterone acetate by November 1988 (personal communication, Committee on Safety of Medicines). Five of these cases were fatal.
231. Dore B, Orget J, Irani J, Aubert J (1990). "Hépatite après traitement par acétate de cyprotérone. A propos d'un cas" [Hepatitis after treatment with cyproterone acetate. Apropos of a case]. J Urol (Paris) (in French). 96 (3): 169–71. ISSN   0248-0018. PMID   2145371.
232. Antoni M, Bourlière M, Toullec J, Maillot A, Botta-Fridlund D, Gauthier A (1991). "Hepatite sub-fulminante d'evolution mortelle a l'acetate de cyproterone" [Fatal subfulminant hepatitis caused by cyproterone acetate]. Gastroenterol. Clin. Biol. (in French). 15 (10): 772–3. ISSN   0399-8320. PMID   1840042.
233. Ohri SK, Gaer JA, Keane PF (February 1991). "Hepatocellular carcinoma and treatment with cyproterone acetate". Br J Urol. 67 (2): 213. doi:10.1111/j.1464-410X.1991.tb15113.x. PMID   1848454.
234. Parys BT, Hamid S, Thomson RG (March 1991). "Severe hepatocellular dysfunction following cyproterone acetate therapy". Br J Urol. 67 (3): 312–3. doi:10.1111/j.1464-410X.1991.tb15142.x. PMID   1827039.
235. Drakos PE, Gez E, Catane R (1992). "Hepatitis due to cyproterone acetate". Eur. J. Cancer. 28A (11): 1931–2. doi:10.1016/0959-8049(92)90041-Y. PMID   1389539.
236. Hassler P, Duchêne R (1992). "Hépatotoxicité de l'acétate de cyprotérone" [Hepatotoxicity of cyproterone acetate]. Rev Med Interne (in French). 13 (3): 245. doi:10.1016/S0248-8663(05)81339-6. PMID   1410910.
237. Roila F, Crinò L, Carloni G, Natalini G (September 1993). "Cyproterone acetate: hepatotoxicity and prostatic cancer treatment". Ann. Oncol. 4 (8): 701. doi:10.1093/oxfordjournals.annonc.a058631. PMID   8241005.
238. Bressollette L, Dubois A, Carlhant D, Morand C, Mottier D, Riche C (1994). "Hépatite mortelle a l'acétate de cyprotérone" [Fatal hepatitis caused by cyproterone acetate]. Therapie (in French). 49 (2): 153. PMID   7817350.
239. Hirsch D, Kovatz S, Bernheim J, Shenkman L (March 1994). "Fatal fulminant hepatitis from cyproterone acetate". Isr. J. Med. Sci. 30 (3): 238–40. PMID   8181926.
240. Kattan J, Spatz A, Culine S, Terrier-Lacombe MJ, Elias D, Droz JP (October 1994). "Hepatocellular carcinoma during hormonotherapy for prostatic cancer". Am. J. Clin. Oncol. 17 (5): 390–2. doi:10.1097/00000421-199410000-00006. PMID   8092108. S2CID   20317818.
241. Watanabe S, Yamasaki S, Tanae A, Hibi I, Honna T (December 1994). "Three cases of hepatocellular carcinoma among cyproterone users. Ad hoc Committee on Androcur Users". Lancet. 344 (8936): 1567–8. doi:10.1016/S0140-6736(94)90373-5. PMID   7983963. S2CID   45906662.
242. Watanabe S, Cui Y, Tanae A, Tanaka T, Fujimoto M, Matsuo Y, Tachibana K, Yamasaki S (September 1997). "Follow-up study of children with precocious puberty treated with cyproterone acetate. Ad hoc Committee for CPA". J Epidemiol. 7 (3): 173–8. doi:10.2188/jea.7.173. PMID   9337516. S2CID   71680776.
243. Pinganaud G, Chaslerie A, Bourdel Marchasson I, Decamps A, Manciet G, Emeriau JP (June 1995). "Cyproterone-induced hepatotoxicity". Ann Pharmacother. 29 (6): 634. doi:10.1177/106002809502900619. PMID   7663042. S2CID   1656405.
244. Rüdiger T, Beckmann J, Queisser W (February 1995). "Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol". Lancet. 345 (8947): 452–3. doi:10.1016/S0140-6736(95)90434-4. PMID   7853970. S2CID   28658581.
245. Castellani P, Bernardini D, Renou C, Zamora C, Portal I, Gauthier A, Botta-Fridlund D (1996). "Hépatite subfulminante mortelle à l'acétate de cyprotérone. Un nouveau cas" [Fatal sub-fulminant hepatitis caused by cyproterone acetate. A new case]. Gastroenterol. Clin. Biol. (in French). 20 (10): 915–6. ISSN   0399-8320. PMID   8991155.
246. Murphy BJ, Collins BJ (October 1996). "Severe hepatitis and liver failure induced by cyproterone acetate". Aust N Z J Med. 26 (5): 724. doi:10.1111/j.1445-5994.1996.tb02956.x. PMID   8958378.
247. Ruiz-Rebollo ML, Polo F, Palenzuela R, Moretó M (1997). "Hepatitis aguda severa por ciproterona" [Severe acute hepatitis due to cyproterone]. Gastroenterol Hepatol (in Spanish). 20 (7): 385. ISSN   0210-5705. PMID   9377242.
248. Lombardi A, Ferrazza P, Castaldi F, Covotta L, Tesoriere A, Urbano V, Midiri G (April 1998). "Necrosi epatica acuta in paziente sottoposto a terapia con ciproterone acetato" [Acute hepatic necrosis in a patient treated with cyproterone acetate]. G Chir (in Italian). 19 (4): 161–3. PMID   9628065.
249. Friedman G, Lamoureux E, Sherker AH (July 1999). "Fatal fulminant hepatic failure due to cyproterone acetate". Dig. Dis. Sci. 44 (7): 1362–3. doi:10.1023/A:1026639432428. PMID   10489919. S2CID   9354740.
250. Garty BZ, Dinari G, Gellvan A, Kauli R (May 1999). "Cirrhosis in a child with hypothalamic syndrome and central precocious puberty treated with cyproterone acetate". Eur. J. Pediatr. 158 (5): 367–70. doi:10.1007/s004310051093. PMID   10333116. S2CID   2736489.
251. Manfredi S, Lenfant L, Gresset AC, Bonnotte B, Lorcerie B, Chauffert B (November 2000). "Carcinome hépatocellulaire sur foie sain potentiellement imputable à la prise au long cours d'acétate de cyprotérone" [Hepatocellular carcinoma in a healthy liver possibly due to long-term use of cyproterone acetate]. Presse Med (in French). 29 (36): 1983. ISSN   0755-4982. PMID   11149080.
252. Giordano N, Nardi P, Santacroce C, Geraci S, Gennari C (September 2001). "Acute hepatitis induced by cyproterone acetate". Ann Pharmacother. 35 (9): 1053–5. doi:10.1177/106002800103500902. PMID   11573856. S2CID   45449852.
253. Kacar S, Akdogan M, Koşar Y, Parlak E, Sasmaz N, Oguz P, Aydog G (July 2002). "Estrogen and cyproterone acetate combination-induced autoimmune hepatitis". J. Clin. Gastroenterol. 35 (1): 98–100. doi:10.1097/00004836-200207000-00023. PMID   12080237.
254. Famularo G, Minisola G, Grieco A, Miele L (September 2005). "Fulminant liver failure caused by cyproterone". Dig Liver Dis. 37 (9): 718–9. doi:10.1016/j.dld.2005.04.018. PMID   15936995.
255. Savidou I, Deutsch M, Soultati AS, Koudouras D, Kafiri G, Dourakis SP (December 2006). "Hepatotoxicity induced by cyproterone acetate: a report of three cases". World J. Gastroenterol. 12 (46): 7551–5. doi: 10.3748/wjg.v12.i46.7551 . PMC   4087608 . PMID   17167851.
256. He JC, Xu P, Peng LB (December 2009). "炔雌醇环丙孕酮致布加综合征1例" [A case of Budd-Chiari syndrome induced by ethinylestradiol and cyproterone acetate]. Zhonghua Gan Zang Bing Za Zhi (in Chinese). 17 (12): 954. doi:10.3760/cma.j.issn.1007-3418.2009.12.020. ISSN   1007-3418. PMID   20038345.
257. "Ethinylestradiol/cyproterone. Budd-Chiari syndrome: case report". Reactions Weekly (1340): 20. February 2011. doi:10.2165/00128415-201113400-00066. ISSN   0114-9954.
258. Kim BH, Kim DJ, Sohn KM, Yang HN, Choi MJ, Lee CW, Choi KC (2009). "잠복간경변 환자에서 cyproterone acetate에 의해 발생한 전격간부전 1예" [A case of fulminant hepatic failure due to cyproterone acetate in a patient with cryptogenic liver cirrhosis]. Korean J Med. 77 (Suppl 1): S31-5. ISSN   1738-9364.
259. Hsu YC, Tai DI (2011). "Unusually high alanine aminotransferase to aspartate aminotransferase ratio in a patient with cyproterone-induced icteric hepatitis". Chang Gung Med J. 34 (6 Suppl): 34–8. PMID   22490456.
260. Abenavoli L, Milic N, Beaugrand M (2013). "Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report". Ann Hepatol. 12 (1): 152–5. doi:10.1016/S1665-2681(19)31399-7. PMID   23293208.
261. Vodička M, Sálek T, Röderová E, Cerný D (2013). "Hepatotoxicita po cyproteron acetátu v léčbě karcinomu prostaty – kazuistika" [Hepatotoxicity induced by cyproterone acetate in the prostate carcinoma treatment - a case report]. Klin Onkol (in Czech). 26 (1): 47–8. doi:10.14735/amko201347. PMID   23528173.
262. Nour E, Mehdi K, Hanene J, Hammami A, Ben Slama A, Ali J (December 2017). "Fatal acute liver failure induced by cyproterone acetate: A new case". Presse Med. 46 (12 Pt 1): 1231–1232. doi:10.1016/j.lpm.2017.09.003. PMID   29129412.
263. "High dose cyproterone and hepatotoxicity". Australian Adverse Drug Reactions Bulletin. 23 (1): 3. 2004. ISSN   1325-8540. High dose cyproterone (50mg, 100mg; Androcur, Androcur-100) is used predominantly for advanced prostate carcinoma. For the year ending June 2003, 59,000 prescriptions were dispensed for the 50mg or 100mg tablets and 97% of patients prescribed these tablets were male. [...] Over the years, ADRAC has received 105 reports implicating high-dose cyproterone. The most common adverse reactions are related to the liver with 32 reports. Other more commonly reported reactions include fatigue, dyspnoea, asthenia, confusion, depression and deep vein thrombosis. [...] All except one of the hepatic reactions involved male patients being treated for prostate cancer, whose ages ranged from 56 to 92 (median: 77) years. Time to onset of liver dysfunction ranged from 4 days to 4 years (median: 4-5 months); only 4 cases had a time to onset under a month.
264. Manso G, Thole Z, Salgueiro E, Revuelta P, Hidalgo A (April 2006). "Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system". Pharmacoepidemiol Drug Saf. 15 (4): 253–9. doi:10.1002/pds.1168. PMID   16294367. S2CID   24515447.
265. "Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS)". Contraception. 56 (5): 275–84. November 1997. doi:10.1016/S0010-7824(97)00158-3. PMID   9437555.
266. Seaman HE, de Vries CS, Farmer RD (2003). "The risk of liver disorders in women prescribed cyproterone acetate in combination with ethinyloestradiol (Dianette): a nested case-control study using the GPRD". Pharmacoepidemiol Drug Saf. 12 (7): 541–50. doi:10.1002/pds.857. PMID   14558177. S2CID   25219358.
267. Roe WD, Geschke K, Pease C (December 2009). "Fatal fulminant hepatitis in a chimpanzee (Pan troglodytes) receiving cyproterone acetate". J. Zoo Wildl. Med. 40 (4): 799–802. doi:10.1638/2009-0031.1. PMID   20063830. S2CID   11762794.
268. Ralph M. Trüeb (26 February 2013). Female Alopecia: Guide to Successful Management. Springer Science & Business Media. pp. 46–. ISBN   978-3-642-35503-5.
269. Ramsay ID, Rushton DH (July 1990). "Reduced serum vitamin B12 levels during oral cyproterone-acetate and ethinyl-oestradiol therapy in women with diffuse androgen-dependent alopecia". Clinical and Experimental Dermatology. 15 (4): 277–81. doi:10.1111/j.1365-2230.1990.tb02089.x. PMID   2145099. S2CID   13431663.
270. Sadock BJ, Sadock VA (2010). Kaplan and Sadock's Pocket Handbook of Clinical Psychiatry. Lippincott Williams & Wilkins. pp. 582–. ISBN   978-1-60547-264-5.
271. Musisi S, Jacobson S (14 April 2015). Brain Degeneration and Dementia in Sub-Saharan Africa. Springer. pp. 60–. ISBN   978-1-4939-2456-1.
272. Ní Mhéalóid Á, Cunniffe G (August 2017). "Optic neuritis secondary to antiandrogen therapy". Ir J Med Sci. 186 (3): 565–570. doi:10.1007/s11845-016-1544-1. PMID   28039596. S2CID   5636178.
273. Grayling M, Jardine DL, McClintock AD, Spar J, Wilton GN (March 2000). "Symptomatic epidural lipomatosis following cyproterone acetate therapy". Aust N Z J Surg. 70 (3): 233–5. doi:10.1046/j.1440-1622.2000.01793.x. PMID   10765911.
274. Mohan D, Taylor R, Mackeith JA (1998). "Cyproterone acetate and striae". International Journal of Psychiatry in Clinical Practice. 2 (2): 147–8. doi:10.3109/13651509809115348. PMID   24946296.
275. Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues". Pharmacol Ther. 24 (3): 367–400. doi:10.1016/0163-7258(84)90010-x. PMID   6205409.
276. van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JH (April 1990). "Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone". Contraception. 41 (4): 345–52. doi:10.1016/0010-7824(90)90034-S. PMID   2139843.
277. Stalvey JR (July 2002). "Inhibition of 3beta-hydroxysteroid dehydrogenase-isomerase in mouse adrenal cells: a direct effect of testosterone". Steroids. 67 (8): 721–31. doi:10.1016/S0039-128X(02)00023-5. PMID   12117620. S2CID   8232250.